Unnamed: 0 float64 0 700k | Date stringlengths 23 23 | Article_title stringlengths 1 250 | Stock_symbol stringlengths 1 5 | Url stringlengths 44 135 | Publisher float64 | Author float64 | Article stringlengths 1 343k ⌀ | Lsa_summary stringlengths 48 53.9k ⌀ | Luhn_summary stringlengths 1 53.9k ⌀ | Textrank_summary stringlengths 1 53.9k ⌀ | Lexrank_summary stringlengths 1 53.9k ⌀ |
|---|---|---|---|---|---|---|---|---|---|---|---|
22,500 | 2023-06-06 00:00:00 UTC | IBM, CVX, or ABBV: Which Dividend Aristocrat Stock is the Most Compelling Pick? | ABBV | https://www.nasdaq.com/articles/ibm-cvx-or-abbv%3A-which-dividend-aristocrat-stock-is-the-most-compelling-pick | null | null | During these uncertain times, investors seek reliable dividend-paying companies that can generate stable income. Dividend aristocrats are companies that have increased their dividends for at least 25 consecutive years and are preferred by investors looking for passive income for their ability to build wealth over time.... | Taking into account total returns (estimated stock price appreciation and dividend yield), Chevron and AbbVie could offer comparable gains over the next 12 months. Using TipRanks’ Stock Comparison Tool, we placed IBM (NYSE:IBM), Chevron (NYSE:CVX), and AbbVie (NYSE:ABBV) against each other to pick the most attractive d... | Using TipRanks’ Stock Comparison Tool, we placed IBM (NYSE:IBM), Chevron (NYSE:CVX), and AbbVie (NYSE:ABBV) against each other to pick the most attractive dividend aristocrat. AbbVie (NYSE:ABBV) Pharmaceutical company AbbVie’s Q1 2023 performance, particularly the impact of biosimilars on blockbuster immunology drug Hu... | Using TipRanks’ Stock Comparison Tool, we placed IBM (NYSE:IBM), Chevron (NYSE:CVX), and AbbVie (NYSE:ABBV) against each other to pick the most attractive dividend aristocrat. AbbVie (NYSE:ABBV) Pharmaceutical company AbbVie’s Q1 2023 performance, particularly the impact of biosimilars on blockbuster immunology drug Hu... | Currently, they see higher upside potential in Chevron and AbbVie stocks than IBM. Using TipRanks’ Stock Comparison Tool, we placed IBM (NYSE:IBM), Chevron (NYSE:CVX), and AbbVie (NYSE:ABBV) against each other to pick the most attractive dividend aristocrat. AbbVie (NYSE:ABBV) Pharmaceutical company AbbVie’s Q1 2023 pe... |
22,501 | 2023-06-05 00:00:00 UTC | Validea Detailed Fundamental Analysis - ABBV | ABBV | https://www.nasdaq.com/articles/validea-detailed-fundamental-analysis-abbv-0 | null | null | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanr... |
22,502 | 2023-06-04 00:00:00 UTC | Guru Fundamental Report for ABBV | ABBV | https://www.nasdaq.com/articles/guru-fundamental-report-for-abbv-34 | null | null | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanr... |
22,503 | 2023-06-03 00:00:00 UTC | Guru Fundamental Report for ABBV | ABBV | https://www.nasdaq.com/articles/guru-fundamental-report-for-abbv-33 | null | null | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanr... |
22,504 | 2023-06-02 00:00:00 UTC | Is Merck Stock A Better Pick Over ABBV? | ABBV | https://www.nasdaq.com/articles/is-merck-stock-a-better-pick-over-abbv | null | null | We believe that AbbVie stock (NYSE: ABBV) is a better pick than its industry peer, Merck stock (NYSE: MRK). MRK stock trades at a slightly higher valuation of 4.8x trailing revenues, compared to 4.2x for AbbVie, and this valuation gap will likely narrow over time in favor of AbbVie, in our view. Looking at stock retur... | We compare a slew of factors, such as historical revenue growth, returns, and valuation, in an interactive dashboard analysis of Merck vs. AbbVie: Which Stock Is A Better Bet? Overall, 2023 will be a painful year for AbbVie, with a decline in sales due to Humira biosimilars, but it will likely return to growth from 202... | Our AbbVie Operating Income Comparison and Merck Operating Income Comparison dashboards have more details. If we compare the current valuation multiples to the historical averages, AbbVie fares better, with its stock currently trading at 4.2x trailing revenues vs. the last five-year average of 5.3x. Our AbbVie (ABBV) V... | We compare a slew of factors, such as historical revenue growth, returns, and valuation, in an interactive dashboard analysis of Merck vs. AbbVie: Which Stock Is A Better Bet? AbbVie’s Revenue Growth Is Better AbbVie’s revenue growth has been better, with a 21.2% average annual growth rate in the last three years, comp... | There is more to the comparison, and in the sections below, we discuss why we believe ABBV stock will offer higher returns than MRK stock in the next three years. We compare a slew of factors, such as historical revenue growth, returns, and valuation, in an interactive dashboard analysis of Merck vs. AbbVie: Which Stoc... |
22,505 | 2023-06-01 00:00:00 UTC | 7 Best Dividend Stocks to Buy Now in June 2023 | ABBV | https://www.nasdaq.com/articles/7-best-dividend-stocks-to-buy-now-in-june-2023 | null | null | Today, I provide my seven best dividend stocks to buy for the month of June. Dividend stocks are a great way to add balance and passive income to a long-term investing portfolio. Compound interest is often called the eighth wonder of the world, and dividends are a great way to accelerate your wealth.
Two of my favorite... | Eric Cuka has positions in AbbVie, Bank of America, Deere, Nike, Schwab U.S. Dividend Equity ETF, and Tractor Supply. Dividend stocks are a great way to add balance and passive income to a long-term investing portfolio. Two of my favorite dividend stocks on the list are Nike (NYSE: NKE) and Qualcomm (NASDAQ: QCOM). | Eric Cuka has positions in AbbVie, Bank of America, Deere, Nike, Schwab U.S. Dividend Equity ETF, and Tractor Supply. The Motley Fool has positions in and recommends Bank of America, Nike, and Qualcomm. The Motley Fool recommends Deere, Tractor Supply, and Vici Properties and recommends the following options: long Janu... | Eric Cuka has positions in AbbVie, Bank of America, Deere, Nike, Schwab U.S. Dividend Equity ETF, and Tractor Supply. Two of my favorite dividend stocks on the list are Nike (NYSE: NKE) and Qualcomm (NASDAQ: QCOM). 10 stocks we like better than Qualcomm When our analyst team has a stock tip, it can pay to listen. | Eric Cuka has positions in AbbVie, Bank of America, Deere, Nike, Schwab U.S. Dividend Equity ETF, and Tractor Supply. Today, I provide my seven best dividend stocks to buy for the month of June. The video was published on June 1, 2023. |
22,506 | 2023-06-01 00:00:00 UTC | Why AbbVie and Amgen Are Moving Lower Today | ABBV | https://www.nasdaq.com/articles/why-abbvie-and-amgen-are-moving-lower-today | null | null | What happened
Shares of the immunology juggernaut AbbVie (NYSE: ABBV) were down by 4% on sky-high volume as of 11 a.m. ET Thursday. That's equivalent to a $7 billion drop in market capitalization.
What's spooking investors this morning? The big loss came after Coherus Biosciences announced a partnership with billionair... | The big loss came after Coherus Biosciences announced a partnership with billionaire Mark Cuban's pharmaceuticals start-up -- known as the Mark Cuban Cost Plus Drug Company -- to sell a biosimilar (a generic biologic) version of AbbVie's flagship anti-inflammatory medication, Humira, at an 85% discount. What happened S... | The big loss came after Coherus Biosciences announced a partnership with billionaire Mark Cuban's pharmaceuticals start-up -- known as the Mark Cuban Cost Plus Drug Company -- to sell a biosimilar (a generic biologic) version of AbbVie's flagship anti-inflammatory medication, Humira, at an 85% discount. What happened S... | The big loss came after Coherus Biosciences announced a partnership with billionaire Mark Cuban's pharmaceuticals start-up -- known as the Mark Cuban Cost Plus Drug Company -- to sell a biosimilar (a generic biologic) version of AbbVie's flagship anti-inflammatory medication, Humira, at an 85% discount. 10 stocks we li... | * They just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! What happened Shares of the immunology juggernaut AbbVie (NYSE: ABBV) were down by 4% on sky-high volume as of 11 a.m. The big loss came after Coherus Biosciences announced a partnership with ... |
22,507 | 2023-06-01 00:00:00 UTC | AstraZeneca (AZN) Discontinues Brazikumab Development | ABBV | https://www.nasdaq.com/articles/astrazeneca-azn-discontinues-brazikumab-development | null | null | AstraZeneca AZN announced the discontinuation of studies on its monoclonal antibody targeting IL23, brazikumab. The candidate was being studied for two indications, Crohn’s disease (CD) and ulcerative colitis (UC), under the inflammatory bowel disease (IBD) development program.
A phase IIb/III INTREPID study was evalua... | Image Source: Zacks Investment Research We would like to remind the investors that in 2016, AstraZeneca first entered into a licensing agreement with Allergan, now part of AbbVie ABBV, for the global rights to brazikumab. However, in early 2020, AstraZeneca announced that it will regain the global rights to brazikumab ... | Click to get this free report AstraZeneca PLC (AZN) : Free Stock Analysis Report Novartis AG (NVS) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Akero Therapeutics, Inc. (AKRO) : Free Stock Analysis Report To read this article on Zacks.com click here. Image Source: Zacks Investment Resear... | Image Source: Zacks Investment Research We would like to remind the investors that in 2016, AstraZeneca first entered into a licensing agreement with Allergan, now part of AbbVie ABBV, for the global rights to brazikumab. Click to get this free report AstraZeneca PLC (AZN) : Free Stock Analysis Report Novartis AG (NVS)... | Image Source: Zacks Investment Research We would like to remind the investors that in 2016, AstraZeneca first entered into a licensing agreement with Allergan, now part of AbbVie ABBV, for the global rights to brazikumab. However, in early 2020, AstraZeneca announced that it will regain the global rights to brazikumab ... |
22,508 | 2023-06-01 00:00:00 UTC | Coherus BioSciences to launch Humira biosimilar at 85% discount | ABBV | https://www.nasdaq.com/articles/coherus-biosciences-to-launch-humira-biosimilar-at-85-discount | null | null | Updates AbbVie shares, adds Amgen shares in paragraph 7, background on competitors in paragraphs 5-6
June 1 (Reuters) - Coherus BioSciences Inc CHRS.O said on Thursday it plans to launch a biosimilar of AbbVie Inc's ABBV.N Humira in July at a list price of $995 per carton, representing a discount of about 85% from the ... | Updates AbbVie shares, adds Amgen shares in paragraph 7, background on competitors in paragraphs 5-6 June 1 (Reuters) - Coherus BioSciences Inc CHRS.O said on Thursday it plans to launch a biosimilar of AbbVie Inc's ABBV.N Humira in July at a list price of $995 per carton, representing a discount of about 85% from the ... | Updates AbbVie shares, adds Amgen shares in paragraph 7, background on competitors in paragraphs 5-6 June 1 (Reuters) - Coherus BioSciences Inc CHRS.O said on Thursday it plans to launch a biosimilar of AbbVie Inc's ABBV.N Humira in July at a list price of $995 per carton, representing a discount of about 85% from the ... | Updates AbbVie shares, adds Amgen shares in paragraph 7, background on competitors in paragraphs 5-6 June 1 (Reuters) - Coherus BioSciences Inc CHRS.O said on Thursday it plans to launch a biosimilar of AbbVie Inc's ABBV.N Humira in July at a list price of $995 per carton, representing a discount of about 85% from the ... | Updates AbbVie shares, adds Amgen shares in paragraph 7, background on competitors in paragraphs 5-6 June 1 (Reuters) - Coherus BioSciences Inc CHRS.O said on Thursday it plans to launch a biosimilar of AbbVie Inc's ABBV.N Humira in July at a list price of $995 per carton, representing a discount of about 85% from the ... |
22,509 | 2023-06-01 00:00:00 UTC | Guru Fundamental Report for ABBV | ABBV | https://www.nasdaq.com/articles/guru-fundamental-report-for-abbv-32 | null | null | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanr... |
22,510 | 2023-06-01 00:00:00 UTC | AstraZeneca to stop developing Crohn's disease drug | ABBV | https://www.nasdaq.com/articles/astrazeneca-to-stop-developing-crohns-disease-drug | null | null | Adds background on drug and AbbVie funding in paragraphs 3 and 4
June 1 (Reuters) - British drugmaker AstraZeneca AZN.L said on Thursday it would stop developing its drug brazikumab to treat inflammatory bowel diseases, including Crohn's disease and ulcerative colitis.
The company said the discontinuation was due to a ... | Adds background on drug and AbbVie funding in paragraphs 3 and 4 June 1 (Reuters) - British drugmaker AstraZeneca AZN.L said on Thursday it would stop developing its drug brazikumab to treat inflammatory bowel diseases, including Crohn's disease and ulcerative colitis. AstraZeneca regained the rights to brazikumab from... | Adds background on drug and AbbVie funding in paragraphs 3 and 4 June 1 (Reuters) - British drugmaker AstraZeneca AZN.L said on Thursday it would stop developing its drug brazikumab to treat inflammatory bowel diseases, including Crohn's disease and ulcerative colitis. AbbVie will stop funding the drug's development, A... | Adds background on drug and AbbVie funding in paragraphs 3 and 4 June 1 (Reuters) - British drugmaker AstraZeneca AZN.L said on Thursday it would stop developing its drug brazikumab to treat inflammatory bowel diseases, including Crohn's disease and ulcerative colitis. AbbVie will stop funding the drug's development, A... | Adds background on drug and AbbVie funding in paragraphs 3 and 4 June 1 (Reuters) - British drugmaker AstraZeneca AZN.L said on Thursday it would stop developing its drug brazikumab to treat inflammatory bowel diseases, including Crohn's disease and ulcerative colitis. AstraZeneca regained the rights to brazikumab from... |
22,511 | 2023-05-31 00:00:00 UTC | SPLG, BRK.B, MRK, ABBV: ETF Inflow Alert | ABBV | https://www.nasdaq.com/articles/splg-brk.b-mrk-abbv%3A-etf-inflow-alert | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR Portfolio S&P 500 ETF (Symbol: SPLG) where we have detected an approximate $108.7 million dollar inflow -- that's a 0.6% increase week over week in outstanding units (from 347,600,000 t... | Among the largest underlying components of SPLG, in trading today Berkshire Hathaway Inc New (Symbol: BRK.B) is down about 0.6%, Merck & Co Inc (Symbol: MRK) is up about 0.4%, and AbbVie Inc (Symbol: ABBV) is up by about 0.2%. These ''units'' can be traded back and forth just like stocks, but can also be created or des... | Among the largest underlying components of SPLG, in trading today Berkshire Hathaway Inc New (Symbol: BRK.B) is down about 0.6%, Merck & Co Inc (Symbol: MRK) is up about 0.4%, and AbbVie Inc (Symbol: ABBV) is up by about 0.2%. For a complete list of holdings, visit the SPLG Holdings page » The chart below shows the one... | Among the largest underlying components of SPLG, in trading today Berkshire Hathaway Inc New (Symbol: BRK.B) is down about 0.6%, Merck & Co Inc (Symbol: MRK) is up about 0.4%, and AbbVie Inc (Symbol: ABBV) is up by about 0.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered... | Among the largest underlying components of SPLG, in trading today Berkshire Hathaway Inc New (Symbol: BRK.B) is down about 0.6%, Merck & Co Inc (Symbol: MRK) is up about 0.4%, and AbbVie Inc (Symbol: ABBV) is up by about 0.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered... |
22,512 | 2023-05-31 00:00:00 UTC | Validea Detailed Fundamental Analysis - ABBV | ABBV | https://www.nasdaq.com/articles/validea-detailed-fundamental-analysis-abbv | null | null | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanr... |
22,513 | 2023-05-31 00:00:00 UTC | What's Ahead for the 10 Stocks That Have Driven Over 80% of U.S. Market Returns So Far in 2023 | ABBV | https://www.nasdaq.com/articles/whats-ahead-for-the-10-stocks-that-have-driven-over-80-of-u.s.-market-returns-so-far-in | null | null | So far, 2023 has been a remarkable year for U.S. equities markets, with the S&P 500 index staging a 10% rally, defying recession fears. However, behind this seemingly positive performance lies a concerning trend.
A select group of technology giants, commonly referred to as the ‘FAANG’ megacaps [minus Netflix (US:NFLX)... | Oil and gas giant Chevron (US:CVX) is down 14.2%, while healthcare heavyweights Pfizer (US:PFE) is down 26.6%, Abbvie (US:ABBV) is down 14.9% and Johnson and Johnson (US:JNJ) is off by 12.6%. A select group of technology giants, commonly referred to as the ‘FAANG’ megacaps [minus Netflix (US:NFLX)], have been driving t... | Oil and gas giant Chevron (US:CVX) is down 14.2%, while healthcare heavyweights Pfizer (US:PFE) is down 26.6%, Abbvie (US:ABBV) is down 14.9% and Johnson and Johnson (US:JNJ) is off by 12.6%. Staggering Influence The magnitude of this group's influence is staggering, with their collective performance driving more than ... | Oil and gas giant Chevron (US:CVX) is down 14.2%, while healthcare heavyweights Pfizer (US:PFE) is down 26.6%, Abbvie (US:ABBV) is down 14.9% and Johnson and Johnson (US:JNJ) is off by 12.6%. A select group of technology giants, commonly referred to as the ‘FAANG’ megacaps [minus Netflix (US:NFLX)], have been driving t... | Oil and gas giant Chevron (US:CVX) is down 14.2%, while healthcare heavyweights Pfizer (US:PFE) is down 26.6%, Abbvie (US:ABBV) is down 14.9% and Johnson and Johnson (US:JNJ) is off by 12.6%. It is a testament to the growing dominance of the tech and AI sectors in the market, particularly in a year when ChatGPT, powere... |
22,514 | 2023-05-31 00:00:00 UTC | AbbVie Says Upadacitinib 30 Mg Meets Primary Goals In SLE Patients In Mid-stage Study | ABBV | https://www.nasdaq.com/articles/abbvie-says-upadacitinib-30-mg-meets-primary-goals-in-sle-patients-in-mid-stage-study | null | null | (RTTNews) - AbbVie Inc. (ABBV), a clinical-stage pharmaceutical company, Wednesday announced the results of its phase 2 SLEek study evaluating upadacitinib (RINVOQ 30 mg), alone and in combination with ABBV-599 high dose (elsubrutinib 60 mg) for systemic lupus erythematosus or SLE in adults.
In the phase 2 of the study... | (RTTNews) - AbbVie Inc. (ABBV), a clinical-stage pharmaceutical company, Wednesday announced the results of its phase 2 SLEek study evaluating upadacitinib (RINVOQ 30 mg), alone and in combination with ABBV-599 high dose (elsubrutinib 60 mg) for systemic lupus erythematosus or SLE in adults. Roopal Thakkar, chief medic... | (RTTNews) - AbbVie Inc. (ABBV), a clinical-stage pharmaceutical company, Wednesday announced the results of its phase 2 SLEek study evaluating upadacitinib (RINVOQ 30 mg), alone and in combination with ABBV-599 high dose (elsubrutinib 60 mg) for systemic lupus erythematosus or SLE in adults. In the phase 2 of the study... | (RTTNews) - AbbVie Inc. (ABBV), a clinical-stage pharmaceutical company, Wednesday announced the results of its phase 2 SLEek study evaluating upadacitinib (RINVOQ 30 mg), alone and in combination with ABBV-599 high dose (elsubrutinib 60 mg) for systemic lupus erythematosus or SLE in adults. In the phase 2 of the study... | (RTTNews) - AbbVie Inc. (ABBV), a clinical-stage pharmaceutical company, Wednesday announced the results of its phase 2 SLEek study evaluating upadacitinib (RINVOQ 30 mg), alone and in combination with ABBV-599 high dose (elsubrutinib 60 mg) for systemic lupus erythematosus or SLE in adults. In the phase 2 of the study... |
22,515 | 2023-05-30 00:00:00 UTC | Should Invesco Dynamic Large Cap Value ETF (PWV) Be on Your Investing Radar? | ABBV | https://www.nasdaq.com/articles/should-invesco-dynamic-large-cap-value-etf-pwv-be-on-your-investing-radar-8 | null | null | Launched on 03/03/2005, the Invesco Dynamic Large Cap Value ETF (PWV) is a passively managed exchange traded fund designed to provide a broad exposure to the Large Cap Value segment of the US equity market.
The fund is sponsored by Invesco. It has amassed assets over $734.77 million, making it one of the average sized ... | Looking at individual holdings, United Parcel Service Inc (UPS) accounts for about 3.72% of total assets, followed by Abbvie Inc (ABBV) and Cisco Systems Inc (CSCO). Click to get this free report Invesco Dynamic Large Cap Value ETF (PWV): ETF Research Reports Cisco Systems, Inc. (CSCO) : Free Stock Analysis Report Unit... | Looking at individual holdings, United Parcel Service Inc (UPS) accounts for about 3.72% of total assets, followed by Abbvie Inc (ABBV) and Cisco Systems Inc (CSCO). Click to get this free report Invesco Dynamic Large Cap Value ETF (PWV): ETF Research Reports Cisco Systems, Inc. (CSCO) : Free Stock Analysis Report Unit... | Click to get this free report Invesco Dynamic Large Cap Value ETF (PWV): ETF Research Reports Cisco Systems, Inc. (CSCO) : Free Stock Analysis Report United Parcel Service, Inc. (UPS) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Vanguard Value ETF (VTV): ETF Research Reports iShares Russ... | Looking at individual holdings, United Parcel Service Inc (UPS) accounts for about 3.72% of total assets, followed by Abbvie Inc (ABBV) and Cisco Systems Inc (CSCO). Click to get this free report Invesco Dynamic Large Cap Value ETF (PWV): ETF Research Reports Cisco Systems, Inc. (CSCO) : Free Stock Analysis Report Unit... |
22,516 | 2023-05-29 00:00:00 UTC | Should You Pick AbbVie Stock Over LLY? | ABBV | https://www.nasdaq.com/articles/should-you-pick-abbvie-stock-over-lly | null | null | We believe that AbbVie stock (NYSE: ABBV) is a better pick than its industry peer, Eli Lilly stock (NYSE: LLY). LLY stock trades at a higher valuation of 14.6x trailing revenues, compared to just 4.2x for AbbVie, and this valuation gap will likely narrow over time in favor of AbbVie, in our view. Looking at stock retu... | We compare a slew of factors, such as historical revenue growth, returns, and valuation, in an interactive dashboard analysis of Eli Lilly vs. AbbVie: Which Stock Is A Better Bet? We believe that AbbVie stock (NYSE: ABBV) is a better pick than its industry peer, Eli Lilly stock (NYSE: LLY). LLY stock trades at a higher... | We compare a slew of factors, such as historical revenue growth, returns, and valuation, in an interactive dashboard analysis of Eli Lilly vs. AbbVie: Which Stock Is A Better Bet? Our AbbVie Operating Income Comparison and Eli Lilly Operating Income Comparison dashboards have more details. Our AbbVie (ABBV) Valuation R... | We compare a slew of factors, such as historical revenue growth, returns, and valuation, in an interactive dashboard analysis of Eli Lilly vs. AbbVie: Which Stock Is A Better Bet? AbbVie’s Revenue Growth Is Better AbbVie’s revenue growth has been much better, with a 21.2% average annual growth rate in the last three ye... | There is more to the comparison, and in the sections below, we discuss why we believe ABBV stock will offer higher returns than LLY stock in the next three years. We compare a slew of factors, such as historical revenue growth, returns, and valuation, in an interactive dashboard analysis of Eli Lilly vs. AbbVie: Which ... |
22,517 | 2023-05-29 00:00:00 UTC | Guru Fundamental Report for ABBV | ABBV | https://www.nasdaq.com/articles/guru-fundamental-report-for-abbv-31 | null | null | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanr... |
22,518 | 2023-05-29 00:00:00 UTC | AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know | ABBV | https://www.nasdaq.com/articles/abbvie-inc.-abbv-is-attracting-investor-attention%3A-here-is-what-you-should-know-7 | null | null | AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.
Over the past month, shares of this drugmaker have returned -9%, compared to the Zacks S&P 500 composite's +3.9%... | Conclusion The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about AbbVie. AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. During this period, the Zacks Large Cap Pharmaceuticals indus... | Last Reported Results and Surprise History AbbVie reported revenues of $12.23 billion in the last reported quarter, representing a year-over-year change of -9.7%. AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. During this period, the Zacks Large Cap Pharmaceuticals industry, which AbbV... | The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for AbbVie. AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. During this period, the Zacks Large Cap Pharmaceuticals industry, whi... | AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. During this period, the Zacks Large Cap Pharmaceuticals industry, which AbbVie falls in, has lost 2%. AbbVie is expected to post earnings of $2.93 per share for the current quarter, representing a year-over-year change of -13.1%. |
22,519 | 2023-05-26 00:00:00 UTC | Guru Fundamental Report for ABBV | ABBV | https://www.nasdaq.com/articles/guru-fundamental-report-for-abbv-30 | null | null | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanr... |
22,520 | 2023-05-25 00:00:00 UTC | 2 Dividend Kings on Sale That Are Yielding More Than 4% | ABBV | https://www.nasdaq.com/articles/2-dividend-kings-on-sale-that-are-yielding-more-than-4 | null | null | Dividend Kings have excellent track records for dividend growth, and are often seen as some of the safest income investments to own. Two dividend growth stocks that may look tempting and that investors may want to take a closer look at today are AbbVie (NYSE: ABBV) and 3M (NYSE: MMM). They have been struggling this yea... | Two dividend growth stocks that may look tempting and that investors may want to take a closer look at today are AbbVie (NYSE: ABBV) and 3M (NYSE: MMM). AbbVie Healthcare company AbbVie pays a dividend yield of 4.1%, which is more than double the S&P 500 average of 1.7%. AbbVie also looks to be in a strong position to ... | AbbVie Healthcare company AbbVie pays a dividend yield of 4.1%, which is more than double the S&P 500 average of 1.7%. Two dividend growth stocks that may look tempting and that investors may want to take a closer look at today are AbbVie (NYSE: ABBV) and 3M (NYSE: MMM). AbbVie also looks to be in a strong position to ... | Two dividend growth stocks that may look tempting and that investors may want to take a closer look at today are AbbVie (NYSE: ABBV) and 3M (NYSE: MMM). AbbVie Healthcare company AbbVie pays a dividend yield of 4.1%, which is more than double the S&P 500 average of 1.7%. AbbVie also looks to be in a strong position to ... | AbbVie Healthcare company AbbVie pays a dividend yield of 4.1%, which is more than double the S&P 500 average of 1.7%. At face value, AbbVie looks like a solid dividend stock. * They just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! |
22,521 | 2023-05-25 00:00:00 UTC | 2 Top Dividend Kings to Buy for the Long Haul | ABBV | https://www.nasdaq.com/articles/2-top-dividend-kings-to-buy-for-the-long-haul-5 | null | null | The market had a difficult 2022. Last year revealed the importance of having safe stocks in your portfolio during times of market volatility.
Enter dividend stocks. What's better than companies that have a track record of consistently paying and increasing dividends? And the most impressive of them all are Dividend Kin... | Long-term investing is the goal When it comes to stock performance this year, both AbbVie and Coca-Cola are underperforming the broader market index. Abbvie Biotech company AbbVie's (NYSE: ABBV) has increased its dividend for 51 consecutive years. Since the spinoff, AbbVie's dividend has increased by more than 250%. | In 2022, Humira generated $21 billion in sales, making up 36% of AbbVie's total revenue. Abbvie Biotech company AbbVie's (NYSE: ABBV) has increased its dividend for 51 consecutive years. Since the spinoff, AbbVie's dividend has increased by more than 250%. | Abbvie Biotech company AbbVie's (NYSE: ABBV) has increased its dividend for 51 consecutive years. Since the spinoff, AbbVie's dividend has increased by more than 250%. Since AbbVie's separation from Abbott, Humira has been critical to its success. | Abbvie Biotech company AbbVie's (NYSE: ABBV) has increased its dividend for 51 consecutive years. Since the spinoff, AbbVie's dividend has increased by more than 250%. Since AbbVie's separation from Abbott, Humira has been critical to its success. |
22,522 | 2023-05-25 00:00:00 UTC | The Zacks Analyst Blog Highlights AbbVie, Intel, Qualcomm, Regeneron and CME Group | ABBV | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights-abbvie-intel-qualcomm-regeneron-and-cme-group | null | null | For Immediate Release
Chicago, IL – May 25, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: AbbVie Inc. ABBV, Intel Corp. ... | Stocks recently featured in the blog include: AbbVie Inc. ABBV, Intel Corp. INTC, Qualcomm Inc. QCOM, Regeneron Pharmaceuticals, Inc. REGN and CME Group Inc. CME. Here are highlights from Wednesday’s Analyst Blog: Top Research Reports for AbbVie, Intel and Qualcomm The Zacks Research Daily presents the best research ou... | Stocks recently featured in the blog include: AbbVie Inc. ABBV, Intel Corp. INTC, Qualcomm Inc. QCOM, Regeneron Pharmaceuticals, Inc. REGN and CME Group Inc. CME. Here are highlights from Wednesday’s Analyst Blog: Top Research Reports for AbbVie, Intel and Qualcomm The Zacks Research Daily presents the best research ou... | Here are highlights from Wednesday’s Analyst Blog: Top Research Reports for AbbVie, Intel and Qualcomm The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including AbbVie Inc., Intel Corp. and Qualcomm Inc. Click to ge... | Today's Research Daily features new research reports on 16 major stocks, including AbbVie Inc., Intel Corp. and Qualcomm Inc. Stocks recently featured in the blog include: AbbVie Inc. ABBV, Intel Corp. INTC, Qualcomm Inc. QCOM, Regeneron Pharmaceuticals, Inc. REGN and CME Group Inc. CME. Here are highlights from Wednes... |
22,523 | 2023-05-25 00:00:00 UTC | Should First Trust Morningstar Dividend Leaders ETF (FDL) Be on Your Investing Radar? | ABBV | https://www.nasdaq.com/articles/should-first-trust-morningstar-dividend-leaders-etf-fdl-be-on-your-investing-radar-6 | null | null | Looking for broad exposure to the Large Cap Value segment of the US equity market? You should consider the First Trust Morningstar Dividend Leaders ETF (FDL), a passively managed exchange traded fund launched on 03/09/2006.
The fund is sponsored by First Trust Advisors. It has amassed assets over $4.72 billion, making ... | Looking at individual holdings, Exxon Mobil Corporation (XOM) accounts for about 9.88% of total assets, followed by Abbvie Inc. (ABBV) and Verizon Communications Inc. (VZ). Click to get this free report First Trust Morningstar Dividend Leaders ETF (FDL): ETF Research Reports Exxon Mobil Corporation (XOM) : Free Stock A... | Looking at individual holdings, Exxon Mobil Corporation (XOM) accounts for about 9.88% of total assets, followed by Abbvie Inc. (ABBV) and Verizon Communications Inc. (VZ). Click to get this free report First Trust Morningstar Dividend Leaders ETF (FDL): ETF Research Reports Exxon Mobil Corporation (XOM) : Free Stock A... | Click to get this free report First Trust Morningstar Dividend Leaders ETF (FDL): ETF Research Reports Exxon Mobil Corporation (XOM) : Free Stock Analysis Report Verizon Communications Inc. (VZ) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Vanguard Value ETF (VTV): ETF Research Reports i... | Looking at individual holdings, Exxon Mobil Corporation (XOM) accounts for about 9.88% of total assets, followed by Abbvie Inc. (ABBV) and Verizon Communications Inc. (VZ). Click to get this free report First Trust Morningstar Dividend Leaders ETF (FDL): ETF Research Reports Exxon Mobil Corporation (XOM) : Free Stock A... |
22,524 | 2023-05-24 00:00:00 UTC | Oversold Conditions For AbbVie | ABBV | https://www.nasdaq.com/articles/oversold-conditions-for-abbvie | null | null | Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.... | A bullish investor could look at ABBV's 29.9 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of ABBV shares: Looking at the chart above, ABBV's low point in i... | A bullish investor could look at ABBV's 29.9 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of ABBV shares: Looking at the chart above, ABBV's low point in i... | In trading on Wednesday, shares of AbbVie Inc (Symbol: ABBV) entered into oversold territory, hitting an RSI reading of 29.9, after changing hands as low as $141.65 per share. A bullish investor could look at ABBV's 29.9 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, a... | In trading on Wednesday, shares of AbbVie Inc (Symbol: ABBV) entered into oversold territory, hitting an RSI reading of 29.9, after changing hands as low as $141.65 per share. A bullish investor could look at ABBV's 29.9 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, a... |
22,525 | 2023-05-24 00:00:00 UTC | Top Research Reports for AbbVie, Intel & Qualcomm | ABBV | https://www.nasdaq.com/articles/top-research-reports-for-abbvie-intel-qualcomm | null | null | Wednesday, May 24, 2023
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including AbbVie Inc. (ABBV), Intel Corp. (INTC) and Qualcomm Inc. (QCOM). These research reports have been hand-picked from the roughly 70 re... | If you want an email notification each time Sheraz publishes a new article, please click here>>> Today's Must Read AbbVie's (ABBV) Skyrizi, Rinvoq Key to Long-Term Growth Intel (INTC) Rides on Mobileye, Diverse Portfolio Strength Qualcomm (QCOM) Remains Poised to Gain from Solid 5G Traction Featured Reports Dupixent Pr... | If you want an email notification each time Sheraz publishes a new article, please click here>>> Today's Must Read AbbVie's (ABBV) Skyrizi, Rinvoq Key to Long-Term Growth Intel (INTC) Rides on Mobileye, Diverse Portfolio Strength Qualcomm (QCOM) Remains Poised to Gain from Solid 5G Traction Featured Reports Dupixent Pr... | If you want an email notification each time Sheraz publishes a new article, please click here>>> Today's Must Read AbbVie's (ABBV) Skyrizi, Rinvoq Key to Long-Term Growth Intel (INTC) Rides on Mobileye, Diverse Portfolio Strength Qualcomm (QCOM) Remains Poised to Gain from Solid 5G Traction Featured Reports Dupixent Pr... | Click to get this free report Intel Corporation (INTC) : Free Stock Analysis Report Regeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis Report Exelon Corporation (EXC) : Free Stock Analysis Report QUALCOMM Incorporated (QCOM) : Free Stock Analysis Report CME Group Inc. (CME) : Free Stock Analysis Report AbbVie... |
22,526 | 2023-05-24 00:00:00 UTC | Noteworthy Wednesday Option Activity: COIN, ABNB, ABBV | ABBV | https://www.nasdaq.com/articles/noteworthy-wednesday-option-activity%3A-coin-abnb-abbv | null | null | Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Coinbase Global Inc (Symbol: COIN), where a total of 93,518 contracts have traded so far, representing approximately 9.4 million underlying shares. That amounts to about 72.5% of COIN's average daily trading vol... | Particularly high volume was seen for the $165 strike put option expiring June 16, 2023, with 7,550 contracts trading so far today, representing approximately 755,000 underlying shares of ABBV. Below is a chart showing ABNB's trailing twelve month trading history, with the $98 strike highlighted in orange: And AbbVie I... | Below is a chart showing ABNB's trailing twelve month trading history, with the $98 strike highlighted in orange: And AbbVie Inc (Symbol: ABBV) saw options trading volume of 37,726 contracts, representing approximately 3.8 million underlying shares or approximately 68.1% of ABBV's average daily trading volume over the ... | Below is a chart showing ABNB's trailing twelve month trading history, with the $98 strike highlighted in orange: And AbbVie Inc (Symbol: ABBV) saw options trading volume of 37,726 contracts, representing approximately 3.8 million underlying shares or approximately 68.1% of ABBV's average daily trading volume over the ... | Below is a chart showing ABNB's trailing twelve month trading history, with the $98 strike highlighted in orange: And AbbVie Inc (Symbol: ABBV) saw options trading volume of 37,726 contracts, representing approximately 3.8 million underlying shares or approximately 68.1% of ABBV's average daily trading volume over the ... |
22,527 | 2023-05-23 00:00:00 UTC | Ironwood (IRWD) to Acquire VectivBio for $1B, Stock Up 3.6% | ABBV | https://www.nasdaq.com/articles/ironwood-irwd-to-acquire-vectivbio-for-%241b-stock-up-3.6 | null | null | Ironwood IRWD announced a definitive agreement to acquire VectivBio VECT, a Switzerland-based biotech company, focused on the development of treatments for severe and rare gastrointestinal conditions.
Shares of Ironwood and VectivBio surged 3.6% and 38.6%, respectively, following the news.
The all-cash transaction is v... | Ironwood, with partner with AbbVie ABBV, co-develops and co-commercializes Linzess in equal shares. Linzess is marketed by AbbVie in Europe and Canada under the brand name, Constella. Ironwood receives royalties on sales of Constella in Europe and Canada from AbbVie. | Click to get this free report Ironwood Pharmaceuticals, Inc. (IRWD) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report ADMA Biologics Inc (ADMA) : Free Stock Analysis Report VectivBio Holding AG (VECT) : Free Stock Analysis Report To read this article on Zacks.com click here. Ironwood, with pa... | Click to get this free report Ironwood Pharmaceuticals, Inc. (IRWD) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report ADMA Biologics Inc (ADMA) : Free Stock Analysis Report VectivBio Holding AG (VECT) : Free Stock Analysis Report To read this article on Zacks.com click here. Ironwood, with pa... | Ironwood, with partner with AbbVie ABBV, co-develops and co-commercializes Linzess in equal shares. Linzess is marketed by AbbVie in Europe and Canada under the brand name, Constella. Ironwood receives royalties on sales of Constella in Europe and Canada from AbbVie. |
22,528 | 2023-05-23 00:00:00 UTC | Noteworthy ETF Outflows: IXJ, ABBV, PFE, ELV | ABBV | https://www.nasdaq.com/articles/noteworthy-etf-outflows%3A-ixj-abbv-pfe-elv | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Global Healthcare ETF (Symbol: IXJ) where we have detected an approximate $72.8 million dollar outflow -- that's a 1.7% decrease week over week (from 48,650,000 to 47,800,000). Among... | Among the largest underlying components of IXJ, in trading today AbbVie Inc (Symbol: ABBV) is down about 1.1%, Pfizer Inc (Symbol: PFE) is off about 0.9%, and Elevance Health Inc (Symbol: ELV) is lower by about 0.3%. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to ... | Among the largest underlying components of IXJ, in trading today AbbVie Inc (Symbol: ABBV) is down about 1.1%, Pfizer Inc (Symbol: PFE) is off about 0.9%, and Elevance Health Inc (Symbol: ELV) is lower by about 0.3%. For a complete list of holdings, visit the IXJ Holdings page » The chart below shows the one year price... | Among the largest underlying components of IXJ, in trading today AbbVie Inc (Symbol: ABBV) is down about 1.1%, Pfizer Inc (Symbol: PFE) is off about 0.9%, and Elevance Health Inc (Symbol: ELV) is lower by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Ch... | Among the largest underlying components of IXJ, in trading today AbbVie Inc (Symbol: ABBV) is down about 1.1%, Pfizer Inc (Symbol: PFE) is off about 0.9%, and Elevance Health Inc (Symbol: ELV) is lower by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Ch... |
22,529 | 2023-05-22 00:00:00 UTC | Why Ironwood Pharmaceuticals Stock Bumped Higher Today | ABBV | https://www.nasdaq.com/articles/why-ironwood-pharmaceuticals-stock-bumped-higher-today | null | null | What happened
Ironwood Pharmaceuticals (NASDAQ: IRWD) is choosing to go the acquisition route to grow its business. On Monday, the company announced it has agreed to acquire clinical-stage biotech VectivBio Holding (NASDAQ: VECT). Investors were clearly warm to that move, as they subsequently traded up Ironwood stock b... | The drug, which was developed in partnership with pharmaceutical sector mainstay AbbVie, was approved in mid-2021. On Monday, the company announced it has agreed to acquire clinical-stage biotech VectivBio Holding (NASDAQ: VECT). In its press release touting the acquisition, Ironwood CEO Tom McCourt described his compa... | The drug, which was developed in partnership with pharmaceutical sector mainstay AbbVie, was approved in mid-2021. What happened Ironwood Pharmaceuticals (NASDAQ: IRWD) is choosing to go the acquisition route to grow its business. In Ironwood's view, apraglutide has clear potential to be a blockbuster drug. | The drug, which was developed in partnership with pharmaceutical sector mainstay AbbVie, was approved in mid-2021. 10 stocks we like better than Ironwood Pharmaceuticals When our analyst team has a stock tip, it can pay to listen. * They just revealed what they believe are the ten best stocks for investors to buy right... | The drug, which was developed in partnership with pharmaceutical sector mainstay AbbVie, was approved in mid-2021. VectivBio is currently developing a drug, apraglutide, to treat short bowel syndrome-associated intestinal failure (SBS-IF). 10 stocks we like better than Ironwood Pharmaceuticals When our analyst team has... |
22,530 | 2023-05-22 00:00:00 UTC | Is Invesco Dynamic Large Cap Value ETF (PWV) a Strong ETF Right Now? | ABBV | https://www.nasdaq.com/articles/is-invesco-dynamic-large-cap-value-etf-pwv-a-strong-etf-right-now-7 | null | null | A smart beta exchange traded fund, the Invesco Dynamic Large Cap Value ETF (PWV) debuted on 03/03/2005, and offers broad exposure to the Style Box - Large Cap Value category of the market.
What Are Smart Beta ETFs?
Products that are based on market cap weighted indexes, which are strategies designed to reflect a specif... | Taking into account individual holdings, United Parcel Service Inc (UPS) accounts for about 3.72% of the fund's total assets, followed by Abbvie Inc (ABBV) and Cisco Systems Inc (CSCO). Click to get this free report Invesco Dynamic Large Cap Value ETF (PWV): ETF Research Reports Cisco Systems, Inc. (CSCO) : Free Stock ... | Click to get this free report Invesco Dynamic Large Cap Value ETF (PWV): ETF Research Reports Cisco Systems, Inc. (CSCO) : Free Stock Analysis Report United Parcel Service, Inc. (UPS) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Vanguard Value ETF (VTV): ETF Research Reports iShares Russ... | Click to get this free report Invesco Dynamic Large Cap Value ETF (PWV): ETF Research Reports Cisco Systems, Inc. (CSCO) : Free Stock Analysis Report United Parcel Service, Inc. (UPS) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Vanguard Value ETF (VTV): ETF Research Reports iShares Russ... | Taking into account individual holdings, United Parcel Service Inc (UPS) accounts for about 3.72% of the fund's total assets, followed by Abbvie Inc (ABBV) and Cisco Systems Inc (CSCO). Click to get this free report Invesco Dynamic Large Cap Value ETF (PWV): ETF Research Reports Cisco Systems, Inc. (CSCO) : Free Stock ... |
22,531 | 2023-05-22 00:00:00 UTC | Should You Invest in the Invesco Dynamic Pharmaceuticals ETF (PJP)? | ABBV | https://www.nasdaq.com/articles/should-you-invest-in-the-invesco-dynamic-pharmaceuticals-etf-pjp-7 | null | null | Launched on 06/23/2005, the Invesco Dynamic Pharmaceuticals ETF (PJP) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Pharma segment of the equity market.
An increasingly popular option among retail and institutional investors, passively managed ETFs offer low costs,... | Looking at individual holdings, Eli Lilly & Co (LLY) accounts for about 6.11% of total assets, followed by Abbvie Inc (ABBV) and Amgen Inc (AMGN). Click to get this free report Invesco Dynamic Pharmaceuticals ETF (PJP): ETF Research Reports Eli Lilly and Company (LLY) : Free Stock Analysis Report Amgen Inc. (AMGN) : Fr... | Click to get this free report Invesco Dynamic Pharmaceuticals ETF (PJP): ETF Research Reports Eli Lilly and Company (LLY) : Free Stock Analysis Report Amgen Inc. (AMGN) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report iShares U.S. Pharmaceuticals ETF (IHE): ETF Research Reports VanEck Pharma... | Click to get this free report Invesco Dynamic Pharmaceuticals ETF (PJP): ETF Research Reports Eli Lilly and Company (LLY) : Free Stock Analysis Report Amgen Inc. (AMGN) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report iShares U.S. Pharmaceuticals ETF (IHE): ETF Research Reports VanEck Pharma... | Looking at individual holdings, Eli Lilly & Co (LLY) accounts for about 6.11% of total assets, followed by Abbvie Inc (ABBV) and Amgen Inc (AMGN). Click to get this free report Invesco Dynamic Pharmaceuticals ETF (PJP): ETF Research Reports Eli Lilly and Company (LLY) : Free Stock Analysis Report Amgen Inc. (AMGN) : Fr... |
22,532 | 2023-05-22 00:00:00 UTC | AbbVie (ABBV) Gets FDA Nod for Lymphoma Drug Epcoritamab | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-gets-fda-nod-for-lymphoma-drug-epcoritamab | null | null | AbbVie ABBV and partner Genmab GMAB announced that the FDA has granted accelerated approval to their T-cell engaging bispecific antibody epcoritamab for treating relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The new drug will be marketed by the trade name of Epkinly. Continued approval for this indication... | AbbVie ABBV and partner Genmab GMAB announced that the FDA has granted accelerated approval to their T-cell engaging bispecific antibody epcoritamab for treating relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Image Source: Zacks Investment Research AbbVie and Genmab announced an oncology collaboration deal ... | AbbVie ABBV and partner Genmab GMAB announced that the FDA has granted accelerated approval to their T-cell engaging bispecific antibody epcoritamab for treating relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Click to get this free report Novartis AG (NVS) : Free Stock Analysis Report Novo Nordisk A/S (NVO)... | AbbVie ABBV and partner Genmab GMAB announced that the FDA has granted accelerated approval to their T-cell engaging bispecific antibody epcoritamab for treating relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Click to get this free report Novartis AG (NVS) : Free Stock Analysis Report Novo Nordisk A/S (NVO)... | AbbVie ABBV and partner Genmab GMAB announced that the FDA has granted accelerated approval to their T-cell engaging bispecific antibody epcoritamab for treating relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Epkinly is the third approved blood cancer drug in AbbVie’s portfolio, the other two being Imbruvic... |
22,533 | 2023-05-22 00:00:00 UTC | Guru Fundamental Report for ABBV | ABBV | https://www.nasdaq.com/articles/guru-fundamental-report-for-abbv-29 | null | null | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanr... |
22,534 | 2023-05-20 00:00:00 UTC | 3 Relatively Safe Stocks to Buy if a Recession Is on the Way | ABBV | https://www.nasdaq.com/articles/3-relatively-safe-stocks-to-buy-if-a-recession-is-on-the-way | null | null | We don't have a modern-day Paul Revere riding a horse through the streets shouting that a recession is coming. But we don't need one, as there are plenty of economists, analysts, and even the Federal Reserve warning that a recession is likely in 2023.
But just because a recession may be on the way, investors don't have... | Here's why three Motley Fool contributors think that AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Johnson & Johnson (NYSE: JNJ) are relatively safe stocks to buy if a recession is declared this year. Stay put through the transition Prosper Junior Bakiny (AbbVie): It may be hard to believe that AbbVie is a s... | Here's why three Motley Fool contributors think that AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Johnson & Johnson (NYSE: JNJ) are relatively safe stocks to buy if a recession is declared this year. Stay put through the transition Prosper Junior Bakiny (AbbVie): It may be hard to believe that AbbVie is a s... | Here's why three Motley Fool contributors think that AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Johnson & Johnson (NYSE: JNJ) are relatively safe stocks to buy if a recession is declared this year. Stay put through the transition Prosper Junior Bakiny (AbbVie): It may be hard to believe that AbbVie is a s... | Here's why three Motley Fool contributors think that AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Johnson & Johnson (NYSE: JNJ) are relatively safe stocks to buy if a recession is declared this year. Stay put through the transition Prosper Junior Bakiny (AbbVie): It may be hard to believe that AbbVie is a s... |
22,535 | 2023-05-20 00:00:00 UTC | 3 No-Brainer Dividend Stocks to Buy With $1,000 Right Now | ABBV | https://www.nasdaq.com/articles/3-no-brainer-dividend-stocks-to-buy-with-%241000-right-now | null | null | Paralysis analysis. It's what happens when you have so many alternatives to evaluate that overthinking causes you to be unable to make a decision.
This condition can easily occur when selecting dividend stocks. Over 4,000 stocks traded on U.S. exchanges offer dividends. But income-seeking investors don't have to suffer... | AbbVie Some might be surprised to see AbbVie (NYSE: ABBV) on a list of no-brainer dividend stocks to buy. The declining sales for Humira are dragging down AbbVie's total revenue, profits, and share price. However, I'd argue that this scenario is what makes AbbVie a great contrarian pick right now. | See the 10 stocks *Stock Advisor returns as of May 15, 2023 Keith Speights has positions in AbbVie, Brookfield Renewable, Brookfield Renewable Partners, and Enterprise Products Partners. AbbVie Some might be surprised to see AbbVie (NYSE: ABBV) on a list of no-brainer dividend stocks to buy. The declining sales for Hum... | AbbVie Some might be surprised to see AbbVie (NYSE: ABBV) on a list of no-brainer dividend stocks to buy. See the 10 stocks *Stock Advisor returns as of May 15, 2023 Keith Speights has positions in AbbVie, Brookfield Renewable, Brookfield Renewable Partners, and Enterprise Products Partners. The declining sales for Hum... | See the 10 stocks *Stock Advisor returns as of May 15, 2023 Keith Speights has positions in AbbVie, Brookfield Renewable, Brookfield Renewable Partners, and Enterprise Products Partners. AbbVie Some might be surprised to see AbbVie (NYSE: ABBV) on a list of no-brainer dividend stocks to buy. The declining sales for Hum... |
22,536 | 2023-05-19 00:00:00 UTC | Pharma Stock Roundup: FDA Nod to ABBV's Rinvoq for New Indication & Other Updates | ABBV | https://www.nasdaq.com/articles/pharma-stock-roundup%3A-fda-nod-to-abbvs-rinvoq-for-new-indication-other-updates | null | null | This week an FDA panel voted in favor of approving Pfizer’s PFE experimental maternal RSV vaccine candidate. The FDA approved AbbVie’s ABBV Rinvoq for its seventh indication, Crohn’s Disease and granted Fast Track Designation to Bayer’s BAYRY asundexian atrial fibrillation program. Roche’s RHHBY BTK inhibitor, fenebrut... | The FDA approved AbbVie’s ABBV Rinvoq for its seventh indication, Crohn’s Disease and granted Fast Track Designation to Bayer’s BAYRY asundexian atrial fibrillation program. Recap of the Week’s Most Important Stories FDA Approves AbbVie’s Rinvoq for Crohn’s Disease: The FDA approved AbbVie’s Rinvoq for the treatment of... | The FDA approved AbbVie’s ABBV Rinvoq for its seventh indication, Crohn’s Disease and granted Fast Track Designation to Bayer’s BAYRY asundexian atrial fibrillation program. Click to get this free report Roche Holding AG (RHHBY) : Free Stock Analysis Report Pfizer Inc. (PFE) : Free Stock Analysis Report Bayer Aktienges... | Recap of the Week’s Most Important Stories FDA Approves AbbVie’s Rinvoq for Crohn’s Disease: The FDA approved AbbVie’s Rinvoq for the treatment of adult patients with moderately to severely active Crohn's disease for patients who have had an inadequate response or intolerance to one or more TNF blockers. Click to get t... | Recap of the Week’s Most Important Stories FDA Approves AbbVie’s Rinvoq for Crohn’s Disease: The FDA approved AbbVie’s Rinvoq for the treatment of adult patients with moderately to severely active Crohn's disease for patients who have had an inadequate response or intolerance to one or more TNF blockers. The FDA approv... |
22,537 | 2023-05-19 00:00:00 UTC | US FDA approves Genmab-AbbVie's blood cancer therapy | ABBV | https://www.nasdaq.com/articles/us-fda-approves-genmab-abbvies-blood-cancer-therapy | null | null | May 19 (Reuters) - The U.S. Food and Drug Administration has approved AbbVie Inc ABBV.N and Danish drugmaker Genmab's GMAB.CO experimental blood cancer therapy for adult patients who have received at least two prior lines of treatment, the companies said on Friday.
(Reporting by Mariam Sunny in Bengaluru; Editing by Sh... | May 19 (Reuters) - The U.S. Food and Drug Administration has approved AbbVie Inc ABBV.N and Danish drugmaker Genmab's GMAB.CO experimental blood cancer therapy for adult patients who have received at least two prior lines of treatment, the companies said on Friday. (Reporting by Mariam Sunny in Bengaluru; Editing by Sh... | May 19 (Reuters) - The U.S. Food and Drug Administration has approved AbbVie Inc ABBV.N and Danish drugmaker Genmab's GMAB.CO experimental blood cancer therapy for adult patients who have received at least two prior lines of treatment, the companies said on Friday. (Reporting by Mariam Sunny in Bengaluru; Editing by Sh... | May 19 (Reuters) - The U.S. Food and Drug Administration has approved AbbVie Inc ABBV.N and Danish drugmaker Genmab's GMAB.CO experimental blood cancer therapy for adult patients who have received at least two prior lines of treatment, the companies said on Friday. (Reporting by Mariam Sunny in Bengaluru; Editing by Sh... | May 19 (Reuters) - The U.S. Food and Drug Administration has approved AbbVie Inc ABBV.N and Danish drugmaker Genmab's GMAB.CO experimental blood cancer therapy for adult patients who have received at least two prior lines of treatment, the companies said on Friday. (Reporting by Mariam Sunny in Bengaluru; Editing by Sh... |
22,538 | 2023-05-19 00:00:00 UTC | US FDA approves Genmab-AbbVie's blood cancer therapy | ABBV | https://www.nasdaq.com/articles/us-fda-approves-genmab-abbvies-blood-cancer-therapy-0 | null | null | Adds details of the drug, background
May 19 (Reuters) - The U.S. Food and Drug Administration has approved AbbVie Inc ABBV.N and Danish drugmaker Genmab's GMAB.CO blood cancer therapy for adult patients who have received at least two prior lines of treatment, the companies said on Friday.
The drug, epcoritamab, to be s... | Adds details of the drug, background May 19 (Reuters) - The U.S. Food and Drug Administration has approved AbbVie Inc ABBV.N and Danish drugmaker Genmab's GMAB.CO blood cancer therapy for adult patients who have received at least two prior lines of treatment, the companies said on Friday. The drug, epcoritamab, to be s... | Adds details of the drug, background May 19 (Reuters) - The U.S. Food and Drug Administration has approved AbbVie Inc ABBV.N and Danish drugmaker Genmab's GMAB.CO blood cancer therapy for adult patients who have received at least two prior lines of treatment, the companies said on Friday. The drug, epcoritamab, to be s... | Adds details of the drug, background May 19 (Reuters) - The U.S. Food and Drug Administration has approved AbbVie Inc ABBV.N and Danish drugmaker Genmab's GMAB.CO blood cancer therapy for adult patients who have received at least two prior lines of treatment, the companies said on Friday. The drug, epcoritamab, to be s... | Adds details of the drug, background May 19 (Reuters) - The U.S. Food and Drug Administration has approved AbbVie Inc ABBV.N and Danish drugmaker Genmab's GMAB.CO blood cancer therapy for adult patients who have received at least two prior lines of treatment, the companies said on Friday. The drug, epcoritamab, to be s... |
22,539 | 2023-05-19 00:00:00 UTC | AbbVie's (ABBV) Rinvoq Gets FDA Nod to Treat Crohn's Disease | ABBV | https://www.nasdaq.com/articles/abbvies-abbv-rinvoq-gets-fda-nod-to-treat-crohns-disease | null | null | AbbVie ABBV announced the FDA approval of its immunology drug, Rinvoq (upadacitinib), a once-daily pill for the treatment of adults with moderately to severely active Crohn's disease who have had an inadequate response or intolerance to one or moretumor necrosis factor blockers. Rinvoq is one of AbbVie’s newer drugs. T... | AbbVie ABBV announced the FDA approval of its immunology drug, Rinvoq (upadacitinib), a once-daily pill for the treatment of adults with moderately to severely active Crohn's disease who have had an inadequate response or intolerance to one or moretumor necrosis factor blockers. Rinvoq is one of AbbVie’s newer drugs. I... | Click to get this free report Novartis AG (NVS) : Free Stock Analysis Report Novo Nordisk A/S (NVO) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Allogene Therapeutics, Inc. (ALLO) : Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie ABBV announced the FDA app... | AbbVie Inc. Price and Consensus AbbVie Inc. price-consensus-chart | AbbVie Inc. Quote Zacks Rank and Stocks to Consider AbbVie currently has a Zacks Rank #3 (Hold). Click to get this free report Novartis AG (NVS) : Free Stock Analysis Report Novo Nordisk A/S (NVO) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free ... | AbbVie ABBV announced the FDA approval of its immunology drug, Rinvoq (upadacitinib), a once-daily pill for the treatment of adults with moderately to severely active Crohn's disease who have had an inadequate response or intolerance to one or moretumor necrosis factor blockers. Rinvoq is one of AbbVie’s newer drugs. I... |
22,540 | 2023-05-19 00:00:00 UTC | Guru Fundamental Report for ABBV | ABBV | https://www.nasdaq.com/articles/guru-fundamental-report-for-abbv-28 | null | null | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanr... |
22,541 | 2023-05-18 00:00:00 UTC | Should Schwab U.S. Dividend Equity ETF (SCHD) Be on Your Investing Radar? | ABBV | https://www.nasdaq.com/articles/should-schwab-u.s.-dividend-equity-etf-schd-be-on-your-investing-radar-7 | null | null | The Schwab U.S. Dividend Equity ETF (SCHD) was launched on 10/20/2011, and is a passively managed exchange traded fund designed to offer broad exposure to the Large Cap Value segment of the US equity market.
The fund is sponsored by Charles Schwab. It has amassed assets over $45.19 billion, making it one of the largest... | Looking at individual holdings, Abbvie Inc (ABBV) accounts for about 4.34% of total assets, followed by Pepsico Inc (PEP) and Cisco Systems Inc (CSCO). Click to get this free report Schwab U.S. Dividend Equity ETF (SCHD): ETF Research Reports Cisco Systems, Inc. (CSCO) : Free Stock Analysis Report PepsiCo, Inc. (PEP) :... | Click to get this free report Schwab U.S. Dividend Equity ETF (SCHD): ETF Research Reports Cisco Systems, Inc. (CSCO) : Free Stock Analysis Report PepsiCo, Inc. (PEP) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Vanguard Value ETF (VTV): ETF Research Reports iShares Russell 1000 Value ET... | Click to get this free report Schwab U.S. Dividend Equity ETF (SCHD): ETF Research Reports Cisco Systems, Inc. (CSCO) : Free Stock Analysis Report PepsiCo, Inc. (PEP) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Vanguard Value ETF (VTV): ETF Research Reports iShares Russell 1000 Value ET... | Looking at individual holdings, Abbvie Inc (ABBV) accounts for about 4.34% of total assets, followed by Pepsico Inc (PEP) and Cisco Systems Inc (CSCO). Click to get this free report Schwab U.S. Dividend Equity ETF (SCHD): ETF Research Reports Cisco Systems, Inc. (CSCO) : Free Stock Analysis Report PepsiCo, Inc. (PEP) :... |
22,542 | 2023-05-18 00:00:00 UTC | Which Pharmaceuticals Stock Is A Better Pick: Johnson & Johnson Or Eliquis' Maker? | ABBV | https://www.nasdaq.com/articles/which-pharmaceuticals-stock-is-a-better-pick%3A-johnson-johnson-or-eliquis-maker | null | null | We believe Bristol Myers Squibb stock (NYSE: BMY) is a better pick than its industry peer, Johnson & Johnson (NYSE: JNJ). J&J trades at a higher valuation of 4.4x trailing revenues, compared to 3.1x for BMS, and this valuation gap will likely narrow over the coming years in favor of BMS, in our view. While BMS has see... | This can partly be attributed to lower contribution from the Covid-19 vaccine and falling sales for Remicade, which now faces biosimilar competition. The company completed the acquisition of heart pump maker – Abiomed – last year, and it is expected to aid the top-line growth of its MedTech segment. Beyond the recovery... | Our Johnson & Johnson Operating Income Comparison and Bristol Myers Squibb Operating Income Comparison dashboards have more details. Our Johnson & Johnson (JNJ) Valuation Ratios Comparison and Bristol Myers Squibb (BMY) Valuation Ratios Comparison have more details. The table below summarizes our revenue and return exp... | We compare a slew of factors, such as historical revenue growth, returns, and valuation, in an interactive dashboard analysis of Johnson & Johnson vs. Bristol Myers Squibb: Which Stock Is A Better Bet? BMS’ Revenue Growth Is Better BMS’ revenue growth has been much better, with a 23.7% average annual growth rate in the... | There is more to the comparison, and in the sections below, we discuss why we believe BMY stock will offer higher returns than JNJ stock in the next three years. BMS’ Revenue Growth Is Better BMS’ revenue growth has been much better, with a 23.7% average annual growth rate in the last three years, compared to 5.1% for ... |
22,543 | 2023-05-18 00:00:00 UTC | EXPLAINER-The latest on tax credit rules in Biden's climate and drugs bill | ABBV | https://www.nasdaq.com/articles/explainer-the-latest-on-tax-credit-rules-in-bidens-climate-and-drugs-bill | null | null | By Jarrett Renshaw and Philip Blenkinsop
May 18 (Reuters) - U.S. President Joe Biden's Inflation Reduction Act (IRA), cheered by some Democrats and the White House as a milestone in the fight against climate change, has also rankled foreign allies and global companies with its economic protectionism and prompted a new ... | The blood thinner Eliquis from Bristol Myers Squibb (BMY.N) and Pfizer (PFE.N), Pfizer's breast cancer drug Ibrance and AbbVie's (ABBV.N) leukemia treatment Imbruvica are likely to be among 10 big-selling medicines subject to the negotiations. By Jarrett Renshaw and Philip Blenkinsop May 18 (Reuters) - U.S. President J... | The blood thinner Eliquis from Bristol Myers Squibb (BMY.N) and Pfizer (PFE.N), Pfizer's breast cancer drug Ibrance and AbbVie's (ABBV.N) leukemia treatment Imbruvica are likely to be among 10 big-selling medicines subject to the negotiations. Since the $739 billion in costs and revenues measure, which also tackles ris... | The blood thinner Eliquis from Bristol Myers Squibb (BMY.N) and Pfizer (PFE.N), Pfizer's breast cancer drug Ibrance and AbbVie's (ABBV.N) leukemia treatment Imbruvica are likely to be among 10 big-selling medicines subject to the negotiations. By Jarrett Renshaw and Philip Blenkinsop May 18 (Reuters) - U.S. President J... | The blood thinner Eliquis from Bristol Myers Squibb (BMY.N) and Pfizer (PFE.N), Pfizer's breast cancer drug Ibrance and AbbVie's (ABBV.N) leukemia treatment Imbruvica are likely to be among 10 big-selling medicines subject to the negotiations. By Jarrett Renshaw and Philip Blenkinsop May 18 (Reuters) - U.S. President J... |
22,544 | 2023-05-17 00:00:00 UTC | Guru Fundamental Report for ABBV | ABBV | https://www.nasdaq.com/articles/guru-fundamental-report-for-abbv-27 | null | null | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanr... |
22,545 | 2023-05-16 00:00:00 UTC | Notable Tuesday Option Activity: PENN, ABBV, KEYS | ABBV | https://www.nasdaq.com/articles/notable-tuesday-option-activity%3A-penn-abbv-keys | null | null | Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in PENN Entertainment Inc (Symbol: PENN), where a total volume of 11,973 contracts has been traded thus far today, a contract volume which is representative of approximately 1.2 million underlying shares (... | Particularly high volume was seen for the $160 strike put option expiring May 19, 2023, with 2,241 contracts trading so far today, representing approximately 224,100 underlying shares of ABBV. Below is a chart showing PENN's trailing twelve month trading history, with the $35 strike highlighted in orange: AbbVie Inc (S... | Below is a chart showing PENN's trailing twelve month trading history, with the $35 strike highlighted in orange: AbbVie Inc (Symbol: ABBV) options are showing a volume of 22,391 contracts thus far today. That number of contracts represents approximately 2.2 million underlying shares, working out to a sizeable 40.7% of... | That number of contracts represents approximately 2.2 million underlying shares, working out to a sizeable 40.7% of ABBV's average daily trading volume over the past month, of 5.5 million shares. Below is a chart showing PENN's trailing twelve month trading history, with the $35 strike highlighted in orange: AbbVie Inc... | Below is a chart showing KEYS's trailing twelve month trading history, with the $150 strike highlighted in orange: For the various different available expirations for PENN options, ABBV options, or KEYS options, visit StockOptionsChannel.com. Below is a chart showing PENN's trailing twelve month trading history, with t... |
22,546 | 2023-05-16 00:00:00 UTC | AstraZeneca to leave leading U.S. drug lobby group | ABBV | https://www.nasdaq.com/articles/astrazeneca-to-leave-leading-u.s.-drug-lobby-group-0 | null | null | By Maggie Fick
LONDON, May 16 (Reuters) - AstraZeneca AZN.L has decided to leave the main U.S. drug lobby group, the Pharmaceutical Research and Manufacturers of America (PhRMA), and pursue other ways of engaging in advocacy at the state and federal level, the company said.
AstraZeneca decided not to continue its membe... | AstraZeneca's exit follows those of AbbVie, maker of blockbuster arthritis drug Humira, and Teva, a leading manufacturer of generic drugs. By Maggie Fick LONDON, May 16 (Reuters) - AstraZeneca AZN.L has decided to leave the main U.S. drug lobby group, the Pharmaceutical Research and Manufacturers of America (PhRMA), an... | AstraZeneca's exit follows those of AbbVie, maker of blockbuster arthritis drug Humira, and Teva, a leading manufacturer of generic drugs. AstraZeneca decided not to continue its membership after a recent assessment of whether it was "the most productive and effective use of (company) resources", a spokesperson for the... | AstraZeneca's exit follows those of AbbVie, maker of blockbuster arthritis drug Humira, and Teva, a leading manufacturer of generic drugs. By Maggie Fick LONDON, May 16 (Reuters) - AstraZeneca AZN.L has decided to leave the main U.S. drug lobby group, the Pharmaceutical Research and Manufacturers of America (PhRMA), an... | AstraZeneca's exit follows those of AbbVie, maker of blockbuster arthritis drug Humira, and Teva, a leading manufacturer of generic drugs. The news, first reported by Politico, marks the trade body's third major departure in six months. AstraZeneca will redirect the funds previously used on its PhRMA membership to cont... |
22,547 | 2023-05-16 00:00:00 UTC | AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It | ABBV | https://www.nasdaq.com/articles/abbvie-inc.-abbv-is-a-trending-stock%3A-facts-to-know-before-betting-on-it-6 | null | null | AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.
Shares of this drugmaker have returned -9.1% over the past month versus the Zacks S&P 500 composite's +0.1% chan... | Bottom Line The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about AbbVie. AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. The Zacks Large Cap Pharmaceuticals industry, to which AbbVi... | Last Reported Results and Surprise History AbbVie reported revenues of $12.23 billion in the last reported quarter, representing a year-over-year change of -9.7%. AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. The Zacks Large Cap Pharmaceuticals industry, to which AbbVie belongs, has g... | Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, AbbVie is rated Zacks Rank #3 (Hold). AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. The Zacks Large Cap Pharmaceuticals industry, to which AbbVie belongs, has ... | Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, AbbVie is rated Zacks Rank #3 (Hold). AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. The Zacks Large Cap Pharmaceuticals industry, to which AbbVie belongs, has ... |
22,548 | 2023-05-15 00:00:00 UTC | Guru Fundamental Report for ABBV | ABBV | https://www.nasdaq.com/articles/guru-fundamental-report-for-abbv-26 | null | null | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanr... |
22,549 | 2023-05-15 00:00:00 UTC | Allergan Aesthetics Says FDA Approves SKINVIVE By JUVEDERM | ABBV | https://www.nasdaq.com/articles/allergan-aesthetics-says-fda-approves-skinvive-by-juvederm | null | null | (RTTNews) - Allergan Aesthetics, an AbbVie company (ABBV), announced Monday the U.S. FDA approval of SKINVIVE by JUVEDERM to improve skin smoothness of the cheeks in adults over the age of 21.
SKINVIVE by JUVEDERM is the first and only hyaluronic acid (HA) intradermal microdroplet injection for skin smoothness availabl... | (RTTNews) - Allergan Aesthetics, an AbbVie company (ABBV), announced Monday the U.S. FDA approval of SKINVIVE by JUVEDERM to improve skin smoothness of the cheeks in adults over the age of 21. SKINVIVE by JUVEDERM is the first and only hyaluronic acid (HA) intradermal microdroplet injection for skin smoothness availabl... | (RTTNews) - Allergan Aesthetics, an AbbVie company (ABBV), announced Monday the U.S. FDA approval of SKINVIVE by JUVEDERM to improve skin smoothness of the cheeks in adults over the age of 21. SKINVIVE by JUVEDERM is a smooth, injectable HA gel that contains a small amount of local anesthetic (lidocaine).1 Unlike other... | (RTTNews) - Allergan Aesthetics, an AbbVie company (ABBV), announced Monday the U.S. FDA approval of SKINVIVE by JUVEDERM to improve skin smoothness of the cheeks in adults over the age of 21. SKINVIVE by JUVEDERM is a smooth, injectable HA gel that contains a small amount of local anesthetic (lidocaine).1 Unlike other... | (RTTNews) - Allergan Aesthetics, an AbbVie company (ABBV), announced Monday the U.S. FDA approval of SKINVIVE by JUVEDERM to improve skin smoothness of the cheeks in adults over the age of 21. SKINVIVE by JUVEDERM is the first and only hyaluronic acid (HA) intradermal microdroplet injection for skin smoothness availabl... |
22,550 | 2023-05-15 00:00:00 UTC | IXJ, MRK, ABBV, PFE: ETF Outflow Alert | ABBV | https://www.nasdaq.com/articles/ixj-mrk-abbv-pfe%3A-etf-outflow-alert | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Global Healthcare ETF (Symbol: IXJ) where we have detected an approximate $154.8 million dollar outflow -- that's a 3.6% decrease week over week (from 50,450,000 to 48,650,000). Amon... | Among the largest underlying components of IXJ, in trading today Merck & Co Inc (Symbol: MRK) is down about 0.5%, AbbVie Inc (Symbol: ABBV) is off about 0.1%, and Pfizer Inc (Symbol: PFE) is lower by about 0.3%. For a complete list of holdings, visit the IXJ Holdings page » The chart below shows the one year price perf... | Among the largest underlying components of IXJ, in trading today Merck & Co Inc (Symbol: MRK) is down about 0.5%, AbbVie Inc (Symbol: ABBV) is off about 0.1%, and Pfizer Inc (Symbol: PFE) is lower by about 0.3%. For a complete list of holdings, visit the IXJ Holdings page » The chart below shows the one year price perf... | Among the largest underlying components of IXJ, in trading today Merck & Co Inc (Symbol: MRK) is down about 0.5%, AbbVie Inc (Symbol: ABBV) is off about 0.1%, and Pfizer Inc (Symbol: PFE) is lower by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel... | Among the largest underlying components of IXJ, in trading today Merck & Co Inc (Symbol: MRK) is down about 0.5%, AbbVie Inc (Symbol: ABBV) is off about 0.1%, and Pfizer Inc (Symbol: PFE) is lower by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel... |
22,551 | 2023-05-12 00:00:00 UTC | See Which Of The Latest 13F Filers Holds AbbVie | ABBV | https://www.nasdaq.com/articles/see-which-of-the-latest-13f-filers-holds-abbvie-7 | null | null | At Holdings Channel, we have reviewed the latest batch of the 46 most recent 13F filings for the 03/31/2023 reporting period, and noticed that AbbVie Inc (Symbol: ABBV) was held by 22 of these funds. When hedge fund managers appear to be thinking alike, we find it is a good idea to take a closer look.
Before we proceed... | At Holdings Channel, we have reviewed the latest batch of the 46 most recent 13F filings for the 03/31/2023 reporting period, and noticed that AbbVie Inc (Symbol: ABBV) was held by 22 of these funds. Worth noting is that FORA Capital LLC, included in this recent batch of 13F filers, exited ABBV common stock as of 03/31... | At Holdings Channel, we have reviewed the latest batch of the 46 most recent 13F filings for the 03/31/2023 reporting period, and noticed that AbbVie Inc (Symbol: ABBV) was held by 22 of these funds. Below, let's take a look at the change in ABBV positions, for this latest batch of 13F filers: Existing -2,118 -$418 Ban... | Existing -2,118 -$418 Banco de Sabadell S.A Existing +359 +$55 Aggregate Change: -98,238 -$20,186 In terms of shares owned, we count 8 of the above funds having increased existing ABBV positions from 12/31/2022 to 03/31/2023, with 10 having decreased their positions and 2 new positions. 4-10 Find out the full Top 10 He... | Existing -2,118 -$418 Banco de Sabadell S.A Existing +359 +$55 Aggregate Change: -98,238 -$20,186 In terms of shares owned, we count 8 of the above funds having increased existing ABBV positions from 12/31/2022 to 03/31/2023, with 10 having decreased their positions and 2 new positions. Looking beyond these particular ... |
22,552 | 2023-05-12 00:00:00 UTC | Guru Fundamental Report for ABBV | ABBV | https://www.nasdaq.com/articles/guru-fundamental-report-for-abbv-25 | null | null | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanr... |
22,553 | 2023-05-11 00:00:00 UTC | Is WisdomTree U.S. High Dividend ETF (DHS) a Strong ETF Right Now? | ABBV | https://www.nasdaq.com/articles/is-wisdomtree-u.s.-high-dividend-etf-dhs-a-strong-etf-right-now-6 | null | null | The WisdomTree U.S. High Dividend ETF (DHS) made its debut on 06/16/2006, and is a smart beta exchange traded fund that provides broad exposure to the Style Box - Large Cap Value category of the market.
What Are Smart Beta ETFs?
The ETF industry has traditionally been dominated by products based on market capitalizatio... | Looking at individual holdings, Exxon Mobil Corp (XOM) accounts for about 5.82% of total assets, followed by Abbvie Inc (ABBV) and Chevron Corp (CVX). Click to get this free report WisdomTree U.S. High Dividend ETF (DHS): ETF Research Reports Chevron Corporation (CVX) : Free Stock Analysis Report Exxon Mobil Corporatio... | Click to get this free report WisdomTree U.S. High Dividend ETF (DHS): ETF Research Reports Chevron Corporation (CVX) : Free Stock Analysis Report Exxon Mobil Corporation (XOM) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Vanguard Value ETF (VTV): ETF Research Reports iShares Russell 100... | Click to get this free report WisdomTree U.S. High Dividend ETF (DHS): ETF Research Reports Chevron Corporation (CVX) : Free Stock Analysis Report Exxon Mobil Corporation (XOM) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Vanguard Value ETF (VTV): ETF Research Reports iShares Russell 100... | Looking at individual holdings, Exxon Mobil Corp (XOM) accounts for about 5.82% of total assets, followed by Abbvie Inc (ABBV) and Chevron Corp (CVX). Click to get this free report WisdomTree U.S. High Dividend ETF (DHS): ETF Research Reports Chevron Corporation (CVX) : Free Stock Analysis Report Exxon Mobil Corporatio... |
22,554 | 2023-05-11 00:00:00 UTC | Should You Invest in the Vanguard Health Care ETF (VHT)? | ABBV | https://www.nasdaq.com/articles/should-you-invest-in-the-vanguard-health-care-etf-vht-7 | null | null | The Vanguard Health Care ETF (VHT) was launched on 01/26/2004, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Broad segment of the equity market.
Retail and institutional investors increasingly turn to passively managed ETFs because they offer low costs, transparenc... | Looking at individual holdings, Unitedhealth Group Inc. (UNH) accounts for about 8.05% of total assets, followed by Johnson & Johnson (JNJ) and Abbvie Inc. (ABBV). Click to get this free report Vanguard Health Care ETF (VHT): ETF Research Reports UnitedHealth Group Incorporated (UNH) : Free Stock Analysis Report Johnso... | Click to get this free report Vanguard Health Care ETF (VHT): ETF Research Reports UnitedHealth Group Incorporated (UNH) : Free Stock Analysis Report Johnson & Johnson (JNJ) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Health Care Select Sector SPDR ETF (XLV): ETF Research Reports iShare... | Click to get this free report Vanguard Health Care ETF (VHT): ETF Research Reports UnitedHealth Group Incorporated (UNH) : Free Stock Analysis Report Johnson & Johnson (JNJ) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Health Care Select Sector SPDR ETF (XLV): ETF Research Reports iShare... | Looking at individual holdings, Unitedhealth Group Inc. (UNH) accounts for about 8.05% of total assets, followed by Johnson & Johnson (JNJ) and Abbvie Inc. (ABBV). Click to get this free report Vanguard Health Care ETF (VHT): ETF Research Reports UnitedHealth Group Incorporated (UNH) : Free Stock Analysis Report Johnso... |
22,555 | 2023-05-10 00:00:00 UTC | Unusual Put Option Trade in Abbvie (ABBV) Worth $4,742.50K | ABBV | https://www.nasdaq.com/articles/unusual-put-option-trade-in-abbvie-abbv-worth-%244742.50k | null | null | On May 10, 2023 at 15:19:36 ET an unusually large $4,742.50K block of Put contracts in Abbvie (ABBV) was bought, with a strike price of $160.00 / share, expiring in 9 day(s) (on May 19, 2023). Fintel tracks all large options trades, and the premium spent on this trade was 3.53 sigmas above the mean, placing it in the 1... | On May 10, 2023 at 15:19:36 ET an unusually large $4,742.50K block of Put contracts in Abbvie (ABBV) was bought, with a strike price of $160.00 / share, expiring in 9 day(s) (on May 19, 2023). AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical... | On May 10, 2023 at 15:19:36 ET an unusually large $4,742.50K block of Put contracts in Abbvie (ABBV) was bought, with a strike price of $160.00 / share, expiring in 9 day(s) (on May 19, 2023). Fintel tracks all large options trades, and the premium spent on this trade was 3.53 sigmas above the mean, placing it in the 1... | Abbvie Declares $1.48 Dividend On February 16, 2023 the company declared a regular quarterly dividend of $1.48 per share ($5.92 annualized). On May 10, 2023 at 15:19:36 ET an unusually large $4,742.50K block of Put contracts in Abbvie (ABBV) was bought, with a strike price of $160.00 / share, expiring in 9 day(s) (on M... | Analyst Price Forecast Suggests 14.68% Upside As of April 24, 2023, the average one-year price target for Abbvie is 168.39. On May 10, 2023 at 15:19:36 ET an unusually large $4,742.50K block of Put contracts in Abbvie (ABBV) was bought, with a strike price of $160.00 / share, expiring in 9 day(s) (on May 19, 2023). Fin... |
22,556 | 2023-05-10 00:00:00 UTC | Guru Fundamental Report for ABBV | ABBV | https://www.nasdaq.com/articles/guru-fundamental-report-for-abbv-24 | null | null | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanr... |
22,557 | 2023-05-10 00:00:00 UTC | Should WisdomTree U.S. High Dividend ETF (DHS) Be on Your Investing Radar? | ABBV | https://www.nasdaq.com/articles/should-wisdomtree-u.s.-high-dividend-etf-dhs-be-on-your-investing-radar-7 | null | null | Designed to provide broad exposure to the Large Cap Value segment of the US equity market, the WisdomTree U.S. High Dividend ETF (DHS) is a passively managed exchange traded fund launched on 06/16/2006.
The fund is sponsored by Wisdomtree. It has amassed assets over $1.26 billion, making it one of the average sized ETF... | Looking at individual holdings, Exxon Mobil Corp (XOM) accounts for about 5.82% of total assets, followed by Abbvie Inc (ABBV) and Chevron Corp (CVX). Click to get this free report WisdomTree U.S. High Dividend ETF (DHS): ETF Research Reports Chevron Corporation (CVX) : Free Stock Analysis Report Exxon Mobil Corporatio... | Looking at individual holdings, Exxon Mobil Corp (XOM) accounts for about 5.82% of total assets, followed by Abbvie Inc (ABBV) and Chevron Corp (CVX). Click to get this free report WisdomTree U.S. High Dividend ETF (DHS): ETF Research Reports Chevron Corporation (CVX) : Free Stock Analysis Report Exxon Mobil Corporatio... | Click to get this free report WisdomTree U.S. High Dividend ETF (DHS): ETF Research Reports Chevron Corporation (CVX) : Free Stock Analysis Report Exxon Mobil Corporation (XOM) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Vanguard Value ETF (VTV): ETF Research Reports iShares Russell 100... | Looking at individual holdings, Exxon Mobil Corp (XOM) accounts for about 5.82% of total assets, followed by Abbvie Inc (ABBV) and Chevron Corp (CVX). Click to get this free report WisdomTree U.S. High Dividend ETF (DHS): ETF Research Reports Chevron Corporation (CVX) : Free Stock Analysis Report Exxon Mobil Corporatio... |
22,558 | 2023-05-10 00:00:00 UTC | Should You Buy Merck Stock At $120? | ABBV | https://www.nasdaq.com/articles/should-you-buy-merck-stock-at-%24120 | null | null | Merck stock (NYSE: MRK) is up 5% in a month, faring slightly better than the broader markets, with the S&P500 up 1%. Although the company posted upbeat Q1 results late last month, we believe MRK stock is fully valued. Merck’s revenues were down 9% to $14.5 billion in Q1’23, compared to our forecast of $13.9 billion. Th... | This growth was driven by continued market share gains and strong performance for the world’s biggest drug (by revenue) – Keytruda – based on expected 2023 sales of about $23 billion, topping the likes of AbbVie’s Humira and Pfizer’s Covid-19 vaccine. The company’s gross margins improved by 670 bps to 72.9% in Q1 due t... | This growth was driven by continued market share gains and strong performance for the world’s biggest drug (by revenue) – Keytruda – based on expected 2023 sales of about $23 billion, topping the likes of AbbVie’s Humira and Pfizer’s Covid-19 vaccine. Although the company posted upbeat Q1 results late last month, we be... | This growth was driven by continued market share gains and strong performance for the world’s biggest drug (by revenue) – Keytruda – based on expected 2023 sales of about $23 billion, topping the likes of AbbVie’s Humira and Pfizer’s Covid-19 vaccine. While Keytruda sales were up 20% to $5.8 billion in Q1, Merck’s Gard... | This growth was driven by continued market share gains and strong performance for the world’s biggest drug (by revenue) – Keytruda – based on expected 2023 sales of about $23 billion, topping the likes of AbbVie’s Humira and Pfizer’s Covid-19 vaccine. Merck’s revenues were down 9% to $14.5 billion in Q1’23, compared to... |
22,559 | 2023-05-09 00:00:00 UTC | Why Viking Therapeutics Stock Wobbled Today | ABBV | https://www.nasdaq.com/articles/why-viking-therapeutics-stock-wobbled-today | null | null | What happened
Shares of clinical-stage biotech Viking Therapeutics (NASDAQ: VKTX) fell by as much as 4.8% on exceptionally low volume during the first hour of trading Tuesday morning. Since this mid-single-digit dip, the biotech's shares have battled back over the course of today's trading session.
As of 2:33 p.m. ET T... | AbbVie (NYSE: ABBV), for instance, has openly admitted that it is on the hunt for high-growth opportunities due to emerging competition in its core area of expertise, immunology. And Viking definitely qualifies as a budget-friendly play for a debt-laden company like AbbVie. AbbVie also doesn't have much in the way of a... | AbbVie (NYSE: ABBV), for instance, has openly admitted that it is on the hunt for high-growth opportunities due to emerging competition in its core area of expertise, immunology. And Viking definitely qualifies as a budget-friendly play for a debt-laden company like AbbVie. AbbVie also doesn't have much in the way of a... | AbbVie (NYSE: ABBV), for instance, has openly admitted that it is on the hunt for high-growth opportunities due to emerging competition in its core area of expertise, immunology. And Viking definitely qualifies as a budget-friendly play for a debt-laden company like AbbVie. AbbVie also doesn't have much in the way of a... | AbbVie (NYSE: ABBV), for instance, has openly admitted that it is on the hunt for high-growth opportunities due to emerging competition in its core area of expertise, immunology. And Viking definitely qualifies as a budget-friendly play for a debt-laden company like AbbVie. AbbVie also doesn't have much in the way of a... |
22,560 | 2023-05-09 00:00:00 UTC | Noteworthy Tuesday Option Activity: HOLX, ABBV, JNJ | ABBV | https://www.nasdaq.com/articles/noteworthy-tuesday-option-activity%3A-holx-abbv-jnj | null | null | Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in Hologic Inc (Symbol: HOLX), where a total of 7,207 contracts have traded so far, representing approximately 720,700 underlying shares. That amounts to about 54.7% of HOLX's average daily trading volume over the past ... | Especially high volume was seen for the $152.50 strike call option expiring May 12, 2023, with 13,777 contracts trading so far today, representing approximately 1.4 million underlying shares of ABBV. Below is a chart showing HOLX's trailing twelve month trading history, with the $90 strike highlighted in orange: AbbVie... | Below is a chart showing HOLX's trailing twelve month trading history, with the $90 strike highlighted in orange: AbbVie Inc (Symbol: ABBV) saw options trading volume of 27,683 contracts, representing approximately 2.8 million underlying shares or approximately 51.3% of ABBV's average daily trading volume over the past... | Below is a chart showing HOLX's trailing twelve month trading history, with the $90 strike highlighted in orange: AbbVie Inc (Symbol: ABBV) saw options trading volume of 27,683 contracts, representing approximately 2.8 million underlying shares or approximately 51.3% of ABBV's average daily trading volume over the past... | Below is a chart showing HOLX's trailing twelve month trading history, with the $90 strike highlighted in orange: AbbVie Inc (Symbol: ABBV) saw options trading volume of 27,683 contracts, representing approximately 2.8 million underlying shares or approximately 51.3% of ABBV's average daily trading volume over the past... |
22,561 | 2023-05-09 00:00:00 UTC | AbbVie Says Health Canada Approves RINVOQ To Treat Adults With Active Nr-axSpA | ABBV | https://www.nasdaq.com/articles/abbvie-says-health-canada-approves-rinvoq-to-treat-adults-with-active-nr-axspa | null | null | (RTTNews) - AbbVie (ABBV) announced Tuesday that Health Canada has approved RINVOQ (upadacitinib, 15 mg), the first oral, once-daily selective and reversible JAK inhibitor for the treatment of adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation who have had an ina... | (RTTNews) - AbbVie (ABBV) announced Tuesday that Health Canada has approved RINVOQ (upadacitinib, 15 mg), the first oral, once-daily selective and reversible JAK inhibitor for the treatment of adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation who have had an ina... | (RTTNews) - AbbVie (ABBV) announced Tuesday that Health Canada has approved RINVOQ (upadacitinib, 15 mg), the first oral, once-daily selective and reversible JAK inhibitor for the treatment of adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation who have had an ina... | (RTTNews) - AbbVie (ABBV) announced Tuesday that Health Canada has approved RINVOQ (upadacitinib, 15 mg), the first oral, once-daily selective and reversible JAK inhibitor for the treatment of adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation who have had an ina... | (RTTNews) - AbbVie (ABBV) announced Tuesday that Health Canada has approved RINVOQ (upadacitinib, 15 mg), the first oral, once-daily selective and reversible JAK inhibitor for the treatment of adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation who have had an ina... |
22,562 | 2023-05-08 00:00:00 UTC | 7 Dividend Stocks That Will Pay You Through Any Market Turmoil | ABBV | https://www.nasdaq.com/articles/7-dividend-stocks-that-will-pay-you-through-any-market-turmoil | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
While there’s nothing quite as exciting as betting everything on a hot growth enterprise, prudent investors may want to consider the best dividend stocks for market crash. In late April, CNBC reported that investors face the threat of persistently higher in... | DUK Duke Energy $98.90 ABBV AbbVie $147.45 BUD Anheuser-Busch $64.68 NEE NextEra Energy $76.06 AbbVie (ABBV) Source: iQoncept/shutterstock.com A pharmaceutical company, AbbVie (NYSE:ABBV) makes a strong case for recession-proof dividend stocks to buy. Under this context, I’m not particularly worried about ABBV’s loss o... | DUK Duke Energy $98.90 ABBV AbbVie $147.45 BUD Anheuser-Busch $64.68 NEE NextEra Energy $76.06 AbbVie (ABBV) Source: iQoncept/shutterstock.com A pharmaceutical company, AbbVie (NYSE:ABBV) makes a strong case for recession-proof dividend stocks to buy. Under this context, I’m not particularly worried about ABBV’s loss o... | DUK Duke Energy $98.90 ABBV AbbVie $147.45 BUD Anheuser-Busch $64.68 NEE NextEra Energy $76.06 AbbVie (ABBV) Source: iQoncept/shutterstock.com A pharmaceutical company, AbbVie (NYSE:ABBV) makes a strong case for recession-proof dividend stocks to buy. Under this context, I’m not particularly worried about ABBV’s loss o... | DUK Duke Energy $98.90 ABBV AbbVie $147.45 BUD Anheuser-Busch $64.68 NEE NextEra Energy $76.06 AbbVie (ABBV) Source: iQoncept/shutterstock.com A pharmaceutical company, AbbVie (NYSE:ABBV) makes a strong case for recession-proof dividend stocks to buy. Under this context, I’m not particularly worried about ABBV’s loss o... |
22,563 | 2023-05-08 00:00:00 UTC | Guru Fundamental Report for ABBV | ABBV | https://www.nasdaq.com/articles/guru-fundamental-report-for-abbv-23 | null | null | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanr... |
22,564 | 2023-05-06 00:00:00 UTC | 1 Relatively Safe Dividend Growth Stock to Buy Hand Over Fist Right Now | ABBV | https://www.nasdaq.com/articles/1-relatively-safe-dividend-growth-stock-to-buy-hand-over-fist-right-now | null | null | If you can buy high-quality dividend stocks when other investors sour on them, you can plant the seeds for robust returns in the future. And that's exactly why it might be worth buying shares of AbbVie (NYSE: ABBV) like it's about to go out of style.
Despite its fully expected, yet ultimately abysmal, first-quarter ear... | But AbbVie's growth is expected to be on the slower side for 2023 and 2024, as some of its older oncology and immunology medicines lose their manufacturing exclusivity and competitors step in to steal market share with generics. AbbVie, a habitual price-hiker that's been singled out by Congress on several occasions, is... | And that's exactly why it might be worth buying shares of AbbVie (NYSE: ABBV) like it's about to go out of style. Here's why AbbVie can do it, and why it could be a smart investment for long-term holding. Why you should consider investing in AbbVie AbbVie is one of the world's pharmaceutical leaders, and that's one of ... | Why you should consider investing in AbbVie AbbVie is one of the world's pharmaceutical leaders, and that's one of the core reasons that it's a relatively safe dividend stock. 10 stocks we like better than AbbVie When our analyst team has a stock tip, it can pay to listen. And that's exactly why it might be worth buyin... | * They just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! And that's exactly why it might be worth buying shares of AbbVie (NYSE: ABBV) like it's about to go out of style. Here's why AbbVie can do it, and why it could be a smart investment for long-t... |
22,565 | 2023-05-06 00:00:00 UTC | Looking for Steady, Passive Income? Buy AbbVie Stock | ABBV | https://www.nasdaq.com/articles/looking-for-steady-passive-income-buy-abbvie-stock | null | null | Dividend growth investing revolves around selecting only the most reliable businesses for your portfolio. This can be measured by consecutive years of dividend growth.
With 51 consecutive years of dividend growth to its credit (including time spent as part of Abbott Laboratories), AbbVie (NYSE: ABBV) certainly has such... | With 51 consecutive years of dividend growth to its credit (including time spent as part of Abbott Laboratories), AbbVie (NYSE: ABBV) certainly has such a record. Humira woes won't hold AbbVie down long The investment world has known for years that AbbVie's mega-hit immunology drug Humira would eventually face its day ... | See the 10 stocks *Stock Advisor returns as of May 1, 2023 Kody Kester has positions in AbbVie, Abbott Laboratories, Amgen, and Johnson & Johnson. With 51 consecutive years of dividend growth to its credit (including time spent as part of Abbott Laboratories), AbbVie (NYSE: ABBV) certainly has such a record. Humira woe... | Humira woes won't hold AbbVie down long The investment world has known for years that AbbVie's mega-hit immunology drug Humira would eventually face its day of reckoning. AbbVie's net revenue dipped by 9.7% year over year to $12.2 billion in Q1. See the 10 stocks *Stock Advisor returns as of May 1, 2023 Kody Kester has... | AbbVie's net revenue dipped by 9.7% year over year to $12.2 billion in Q1. See the 10 stocks *Stock Advisor returns as of May 1, 2023 Kody Kester has positions in AbbVie, Abbott Laboratories, Amgen, and Johnson & Johnson. With 51 consecutive years of dividend growth to its credit (including time spent as part of Abbott... |
22,566 | 2023-05-06 00:00:00 UTC | 3 Great Income Stocks That Retirees Should Love | ABBV | https://www.nasdaq.com/articles/3-great-income-stocks-that-retirees-should-love | null | null | Most Americans don't have to wait until they're retired to know that Social Security benefits won't be enough to maintain their current lifestyle. If they pay any attention to retirement planning advice, they know they will need other sources of income as well. Investing in dividend stocks is one great way to generate ... | They picked AbbVie (NYSE: ABBV), Johnson & Johnson (NYSE: JNJ), and Pfizer (NYSE: PFE). A new era, but the same great dividend Keith Speights (AbbVie): There's no question that AbbVie is entering into a new era in its history. However, one important thing hasn't changed for AbbVie in this new era: The company still off... | They picked AbbVie (NYSE: ABBV), Johnson & Johnson (NYSE: JNJ), and Pfizer (NYSE: PFE). A new era, but the same great dividend Keith Speights (AbbVie): There's no question that AbbVie is entering into a new era in its history. However, one important thing hasn't changed for AbbVie in this new era: The company still off... | AbbVie is a Dividend King with 51 consecutive years of dividend increases (41 of those years the dividend came from its being part of parent company Abbott Laboratories). They picked AbbVie (NYSE: ABBV), Johnson & Johnson (NYSE: JNJ), and Pfizer (NYSE: PFE). A new era, but the same great dividend Keith Speights (AbbVie... | AbbVie is a Dividend King with 51 consecutive years of dividend increases (41 of those years the dividend came from its being part of parent company Abbott Laboratories). They picked AbbVie (NYSE: ABBV), Johnson & Johnson (NYSE: JNJ), and Pfizer (NYSE: PFE). A new era, but the same great dividend Keith Speights (AbbVie... |
22,567 | 2023-05-05 00:00:00 UTC | XLV: 5 Reasons to Put This Healthcare ETF on Your Radar | ABBV | https://www.nasdaq.com/articles/xlv%3A-5-reasons-to-put-this-healthcare-etf-on-your-radar | null | null | The Healthcare Select Sector SPDR ETF (NYSEARCA:XLV) has had a relatively quiet 2023 thus far. XLV has a loss of about 1.1% year-to-date, but it looks like an attractive investment vehicle in the current environment -- here are five reasons why.
1. Healthcare is Defensive
Between soaring inflation, rising interest ra... | For example, top 10 holding AbbVie (NYSE:ABBV) trades at just 13.4 times earnings, while Bristol Myers (NYSE:BMY) trades at an even cheaper 8.3 times earnings. Stable, Growing Dividends Many of these individual stocks listed above also feature some pretty attractive dividend yields, such as AbbVie’s 4%, Bristol Myers’ ... | For example, top 10 holding AbbVie (NYSE:ABBV) trades at just 13.4 times earnings, while Bristol Myers (NYSE:BMY) trades at an even cheaper 8.3 times earnings. Stable, Growing Dividends Many of these individual stocks listed above also feature some pretty attractive dividend yields, such as AbbVie’s 4%, Bristol Myers’ ... | For example, top 10 holding AbbVie (NYSE:ABBV) trades at just 13.4 times earnings, while Bristol Myers (NYSE:BMY) trades at an even cheaper 8.3 times earnings. Stable, Growing Dividends Many of these individual stocks listed above also feature some pretty attractive dividend yields, such as AbbVie’s 4%, Bristol Myers’ ... | For example, top 10 holding AbbVie (NYSE:ABBV) trades at just 13.4 times earnings, while Bristol Myers (NYSE:BMY) trades at an even cheaper 8.3 times earnings. Stable, Growing Dividends Many of these individual stocks listed above also feature some pretty attractive dividend yields, such as AbbVie’s 4%, Bristol Myers’ ... |
22,568 | 2023-05-05 00:00:00 UTC | VYM, JPM, CVX, ABBV: ETF Inflow Alert | ABBV | https://www.nasdaq.com/articles/vym-jpm-cvx-abbv%3A-etf-inflow-alert | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard High Dividend Yield ETF (Symbol: VYM) where we have detected an approximate $233.6 million dollar inflow -- that's a 0.5% increase week over week in outstanding units (from 463,654,... | Among the largest underlying components of VYM, in trading today JPMorgan Chase & Co (Symbol: JPM) is up about 1.9%, Chevron Corporation (Symbol: CVX) is up about 2.6%, and AbbVie Inc (Symbol: ABBV) is up by about 0.8%. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed ... | Among the largest underlying components of VYM, in trading today JPMorgan Chase & Co (Symbol: JPM) is up about 1.9%, Chevron Corporation (Symbol: CVX) is up about 2.6%, and AbbVie Inc (Symbol: ABBV) is up by about 0.8%. For a complete list of holdings, visit the VYM Holdings page » The chart below shows the one year pr... | Among the largest underlying components of VYM, in trading today JPMorgan Chase & Co (Symbol: JPM) is up about 1.9%, Chevron Corporation (Symbol: CVX) is up about 2.6%, and AbbVie Inc (Symbol: ABBV) is up by about 0.8%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF... | Among the largest underlying components of VYM, in trading today JPMorgan Chase & Co (Symbol: JPM) is up about 1.9%, Chevron Corporation (Symbol: CVX) is up about 2.6%, and AbbVie Inc (Symbol: ABBV) is up by about 0.8%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF... |
22,569 | 2023-05-04 00:00:00 UTC | 7 Stock Upgrades and Downgrades Alerts You Cannot Ignore | ABBV | https://www.nasdaq.com/articles/7-stock-upgrades-and-downgrades-alerts-you-cannot-ignore | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Analyst stock upgrades and downgrades create powerful headlines that will move the underlying shares. Investors should take advantage of the price swings analysts create, especially when they make the wrong calls.
Stock price changes are noisy. Investors ma... | ABBV AbbVie $149.25 INTC Intel $30.65 MSFT Microsoft $304.40 MXL MaxLinear $24.14 NET Cloudflare $41.90 SNY Sanofi $ 54.22 TSCO Tractor Supply $243.31 AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com AbbVie (NYSE:ABBV) earned multiple “buy” ratings in the last week. In Q1/2023, AbbVie posted revenue and earnings de... | ABBV AbbVie $149.25 INTC Intel $30.65 MSFT Microsoft $304.40 MXL MaxLinear $24.14 NET Cloudflare $41.90 SNY Sanofi $ 54.22 TSCO Tractor Supply $243.31 AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com AbbVie (NYSE:ABBV) earned multiple “buy” ratings in the last week. In Q1/2023, AbbVie posted revenue and earnings de... | ABBV AbbVie $149.25 INTC Intel $30.65 MSFT Microsoft $304.40 MXL MaxLinear $24.14 NET Cloudflare $41.90 SNY Sanofi $ 54.22 TSCO Tractor Supply $243.31 AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com AbbVie (NYSE:ABBV) earned multiple “buy” ratings in the last week. In Q1/2023, AbbVie posted revenue and earnings de... | ABBV AbbVie $149.25 INTC Intel $30.65 MSFT Microsoft $304.40 MXL MaxLinear $24.14 NET Cloudflare $41.90 SNY Sanofi $ 54.22 TSCO Tractor Supply $243.31 AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com AbbVie (NYSE:ABBV) earned multiple “buy” ratings in the last week. In Q1/2023, AbbVie posted revenue and earnings de... |
22,570 | 2023-05-04 00:00:00 UTC | 7 Dividend-Paying Large-Cap Stocks to Buy in May | ABBV | https://www.nasdaq.com/articles/7-dividend-paying-large-cap-stocks-to-buy-in-may-0 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Large-cap stocks are those that have a market capitalization above $10 billion and are synonymously known as big cap stocks. A company’s market capitalization is calculated by multiplying the share price by the number of shares outstanding. By that metric, ... | The earnings beat, though small, suggests AbbVie is strategically doing what it should be, in promoting the other parts of its portfolio and pushing for greater sales and market share. AVGO Broadcom $610.16 RTX Raytheon $95.92 LIN Linde $360.80 ABBV AbbVie $147.36 HSY Hershey $274.64 MA Mastercard $376.12 UNH UnitedHea... | AVGO Broadcom $610.16 RTX Raytheon $95.92 LIN Linde $360.80 ABBV AbbVie $147.36 HSY Hershey $274.64 MA Mastercard $376.12 UNH UnitedHealth Group $487.28 Broadcom (AVGO) Source: Sasima / Shutterstock.com Broadcom (NASDAQ:AVGO) is a semiconductor and infrastructure software solutions firm with a strong history. AbbVie (A... | AVGO Broadcom $610.16 RTX Raytheon $95.92 LIN Linde $360.80 ABBV AbbVie $147.36 HSY Hershey $274.64 MA Mastercard $376.12 UNH UnitedHealth Group $487.28 Broadcom (AVGO) Source: Sasima / Shutterstock.com Broadcom (NASDAQ:AVGO) is a semiconductor and infrastructure software solutions firm with a strong history. AbbVie (A... | AbbVie (ABBV) Source: Valeriya Zankovych / Shutterstock.com Now is the time to invest in AbbVie (NYSE:ABBV), even as Humira sales decline sharply. AVGO Broadcom $610.16 RTX Raytheon $95.92 LIN Linde $360.80 ABBV AbbVie $147.36 HSY Hershey $274.64 MA Mastercard $376.12 UNH UnitedHealth Group $487.28 Broadcom (AVGO) Sour... |
22,571 | 2023-05-04 00:00:00 UTC | June 23rd Options Now Available For AbbVie (ABBV) | ABBV | https://www.nasdaq.com/articles/june-23rd-options-now-available-for-abbvie-abbv | null | null | Investors in AbbVie Inc (Symbol: ABBV) saw new options begin trading today, for the June 23rd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new June 23rd contracts and identified one put and one call contract of particular interest.
The put contract a... | Of course, a lot of upside could potentially be left on the table if ABBV shares really soar, which is why looking at the trailing twelve month trading history for AbbVie Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ABBV's trailing twelve month trading history, with the... | Below is a chart showing ABBV's trailing twelve month trading history, with the $150.00 strike highlighted in red: Considering the fact that the $150.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the pos... | Below is a chart showing the trailing twelve month trading history for AbbVie Inc, and highlighting in green where the $145.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $150.00 strike price has a current bid of $3.25. Below is a chart showing ABB... | At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new June 23rd contracts and identified one put and one call contract of particular interest. Below is a chart showing ABBV's trailing twelve month trading history, with the $150.00 strike highlighted in red: Consideri... |
22,572 | 2023-05-03 00:00:00 UTC | 2 Things About AbbVie That Investors Are Ignoring | ABBV | https://www.nasdaq.com/articles/2-things-about-abbvie-that-investors-are-ignoring | null | null | Investors were ready for declines in AbbVie's (NYSE: ABBV) blockbuster immunology drug Humira. The product now is facing competition in the U.S. So, seeing a 26% drop in Humira's U.S. first-quarter sales wasn't a surprise. And AbbVie has been grooming its newer immunology drugs -- Rinvoq and Skyrizi -- to eventually co... | And AbbVie has been grooming its newer immunology drugs -- Rinvoq and Skyrizi -- to eventually compensate for Humira and even drive further growth. Importantly, both drugs' growth rates during the first quarter met AbbVie's expectations -- and they're on track to, together, bring in $11 billion in revenue this year. Ev... | And AbbVie has been grooming its newer immunology drugs -- Rinvoq and Skyrizi -- to eventually compensate for Humira and even drive further growth. That's probably why, when Rinvoq and Skyrizi missed some analysts' forecasts for the quarter, AbbVie shares slipped. Investors were ready for declines in AbbVie's (NYSE: AB... | And AbbVie has been grooming its newer immunology drugs -- Rinvoq and Skyrizi -- to eventually compensate for Humira and even drive further growth. Importantly, both drugs' growth rates during the first quarter met AbbVie's expectations -- and they're on track to, together, bring in $11 billion in revenue this year. Ae... | That's probably why, when Rinvoq and Skyrizi missed some analysts' forecasts for the quarter, AbbVie shares slipped. Importantly, both drugs' growth rates during the first quarter met AbbVie's expectations -- and they're on track to, together, bring in $11 billion in revenue this year. Investors were ready for declines... |
22,573 | 2023-05-03 00:00:00 UTC | Guru Fundamental Report for ABBV | ABBV | https://www.nasdaq.com/articles/guru-fundamental-report-for-abbv-22 | null | null | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanr... |
22,574 | 2023-05-02 00:00:00 UTC | Vertex Pharmaceuticals Just Lost a Potential Rival. Is the Stock a Buy? | ABBV | https://www.nasdaq.com/articles/vertex-pharmaceuticals-just-lost-a-potential-rival.-is-the-stock-a-buy | null | null | Vertex Pharmaceuticals (NASDAQ: VRTX) is the global leader in cystic fibrosis (CF) treatment. The company is known for its combination therapies targeting a defective protein that causes the disease's devastating symptoms.
But one possible threat to market share waited in the wings. AbbVie (NYSE: ABBV) had shepherded i... | If AbbVie's candidate eventually demonstrated superiority to Trikafta, and if the company could have offered such a therapy at a lower price, then it might have hurt Vertex's market share. AbbVie (NYSE: ABBV) had shepherded its own combination-therapy candidate -- also targeting the defective protein -- into phase 2 st... | AbbVie (NYSE: ABBV) had shepherded its own combination-therapy candidate -- also targeting the defective protein -- into phase 2 studies. Just recently, though, AbbVie ended development of the potential treatment and dropped its CF program. AbbVie is forecast to become the No. | This treatment represented AbbVie's entire CF program, so it's not surprising the company decided to completely exit CF. If AbbVie's candidate eventually demonstrated superiority to Trikafta, and if the company could have offered such a therapy at a lower price, then it might have hurt Vertex's market share. AbbVie (NY... | This treatment represented AbbVie's entire CF program, so it's not surprising the company decided to completely exit CF. AbbVie (NYSE: ABBV) had shepherded its own combination-therapy candidate -- also targeting the defective protein -- into phase 2 studies. Just recently, though, AbbVie ended development of the potent... |
22,575 | 2023-05-02 00:00:00 UTC | AmerisourceBergen raises profit forecast on demand for pricier specialty drugs | ABBV | https://www.nasdaq.com/articles/amerisourcebergen-raises-profit-forecast-on-demand-for-pricier-specialty-drugs | null | null | May 2 (Reuters) - AmerisourceBergen Corp ABC.N on Tuesday raised full-year profit forecast and beat estimates for the second quarter, as the drug distributor benefited from demand for costly specialty therapies.
The Pennsylvania-based company has been looking to diversify its specialty services business, through which ... | It is also expected to benefit from the launch of cheaper versions of some branded drugs, as drugmakers like AbbVie Inc ABBV.N face looming patent cliffs for its top-selling drugs, like Humira for rheumatoid arthritis treatment that lost its exclusivity this year in the US market. May 2 (Reuters) - AmerisourceBergen Co... | It is also expected to benefit from the launch of cheaper versions of some branded drugs, as drugmakers like AbbVie Inc ABBV.N face looming patent cliffs for its top-selling drugs, like Humira for rheumatoid arthritis treatment that lost its exclusivity this year in the US market. May 2 (Reuters) - AmerisourceBergen Co... | It is also expected to benefit from the launch of cheaper versions of some branded drugs, as drugmakers like AbbVie Inc ABBV.N face looming patent cliffs for its top-selling drugs, like Humira for rheumatoid arthritis treatment that lost its exclusivity this year in the US market. May 2 (Reuters) - AmerisourceBergen Co... | It is also expected to benefit from the launch of cheaper versions of some branded drugs, as drugmakers like AbbVie Inc ABBV.N face looming patent cliffs for its top-selling drugs, like Humira for rheumatoid arthritis treatment that lost its exclusivity this year in the US market. AmerisourceBergen now expects adjusted... |
22,576 | 2023-05-02 00:00:00 UTC | Vertex Pharmaceuticals Stock Is an Even Better Buy Now Thanks to AbbVie | ABBV | https://www.nasdaq.com/articles/vertex-pharmaceuticals-stock-is-an-even-better-buy-now-thanks-to-abbvie | null | null | While the overall market plummeted last year, shares of Vertex Pharmaceuticals (NASDAQ: VRTX) skyrocketed 31%. So far in 2023, the stock is up nearly 20%.
I've shouted from the rooftop for a long time that Vertex is one of the best biotech stocks around. And I'm more convinced of that than ever after a key development ... | When asked by an analyst if AbbVie has any other asset in early development that it might move forward, Hudson replied that the company doesn't have any other CF pipeline candidates. Here's why Vertex stock is an even better buy now thanks to AbbVie (NYSE: ABBV). Throwing in the towel AbbVie had been evaluating a tripl... | Throwing in the towel AbbVie had been evaluating a triple-drug combo targeting cystic fibrosis (CF) in phase 2 testing. Here's why Vertex stock is an even better buy now thanks to AbbVie (NYSE: ABBV). Chief Scientific Officer Tom Hudson said in the Q1 call that AbbVie recently analyzed data from the phase 2 study. | Here's why Vertex stock is an even better buy now thanks to AbbVie (NYSE: ABBV). Throwing in the towel AbbVie had been evaluating a triple-drug combo targeting cystic fibrosis (CF) in phase 2 testing. Chief Scientific Officer Tom Hudson said in the Q1 call that AbbVie recently analyzed data from the phase 2 study. | Throwing in the towel AbbVie had been evaluating a triple-drug combo targeting cystic fibrosis (CF) in phase 2 testing. This wasn't AbbVie's first setback in CF. Here's why Vertex stock is an even better buy now thanks to AbbVie (NYSE: ABBV). |
22,577 | 2023-05-02 00:00:00 UTC | High-Yield Pfizer Falls Off The COVID Cliff, And Survives | ABBV | https://www.nasdaq.com/articles/high-yield-pfizer-falls-off-the-covid-cliff-and-survives | null | null | Pfizer (NYSE: PFE) was expected to post a significant decline in revenue and earnings because of the slowing COVID business, and it did. However, the takeaway from the report is that business is better than expected, the company is growing at the core level, and the pipeline of new products is robust. That’s important ... | Shares of Pfizer trade at only 11.5X earnings compared to 14X for AbbVie (NYSE: ABBV), 16X for Merck & Co. (NYSE: MRK) and an even higher 49X for AstraZeneca (NYSE: AZN) and none of them have a comparable yield. AbbVie is the closest at 3.85%, but it is facing 1 of the toughest patent cliffs on the docket. AbbVie’s Hum... | Shares of Pfizer trade at only 11.5X earnings compared to 14X for AbbVie (NYSE: ABBV), 16X for Merck & Co. (NYSE: MRK) and an even higher 49X for AstraZeneca (NYSE: AZN) and none of them have a comparable yield. AbbVie is the closest at 3.85%, but it is facing 1 of the toughest patent cliffs on the docket. AbbVie’s Hum... | Shares of Pfizer trade at only 11.5X earnings compared to 14X for AbbVie (NYSE: ABBV), 16X for Merck & Co. (NYSE: MRK) and an even higher 49X for AstraZeneca (NYSE: AZN) and none of them have a comparable yield. AbbVie is the closest at 3.85%, but it is facing 1 of the toughest patent cliffs on the docket. AbbVie’s Hum... | Shares of Pfizer trade at only 11.5X earnings compared to 14X for AbbVie (NYSE: ABBV), 16X for Merck & Co. (NYSE: MRK) and an even higher 49X for AstraZeneca (NYSE: AZN) and none of them have a comparable yield. AbbVie is the closest at 3.85%, but it is facing 1 of the toughest patent cliffs on the docket. AbbVie’s Hum... |
22,578 | 2023-05-02 00:00:00 UTC | Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know | ABBV | https://www.nasdaq.com/articles/investors-heavily-search-abbvie-inc.-abbv%3A-here-is-what-you-need-to-know-5 | null | null | AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.
Shares of this drugmaker have returned -4.2% over the past month versus the Zacks S&P 500 composite's +1.5% chan... | Conclusion The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about AbbVie. AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. The Zacks Large Cap Pharmaceuticals industry, to which AbbVie... | Last Reported Results and Surprise History AbbVie reported revenues of $12.23 billion in the last reported quarter, representing a year-over-year change of -9.7%. AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. The Zacks Large Cap Pharmaceuticals industry, to which AbbVie belongs, has g... | The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for AbbVie. AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. The Zacks Large Cap Pharmaceuticals industry, to which AbbVie belongs... | The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for AbbVie. AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. The Zacks Large Cap Pharmaceuticals industry, to which AbbVie belongs... |
22,579 | 2023-05-01 00:00:00 UTC | Unusual Put Option Trade in Abbvie (ABBV) Worth $1,585.00K | ABBV | https://www.nasdaq.com/articles/unusual-put-option-trade-in-abbvie-abbv-worth-%241585.00k | null | null | On May 1, 2023 at 11:32:44 ET an unusually large $1,585.00K block of Put contracts in Abbvie (ABBV) was sold, with a strike price of $150.00 / share, expiring in 627 day(s) (on January 17, 2025). Fintel tracks all large options trades, and the premium spent on this trade was 5.38 sigmas above the mean, placing it in th... | On May 1, 2023 at 11:32:44 ET an unusually large $1,585.00K block of Put contracts in Abbvie (ABBV) was sold, with a strike price of $150.00 / share, expiring in 627 day(s) (on January 17, 2025). AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medi... | On May 1, 2023 at 11:32:44 ET an unusually large $1,585.00K block of Put contracts in Abbvie (ABBV) was sold, with a strike price of $150.00 / share, expiring in 627 day(s) (on January 17, 2025). Fintel tracks all large options trades, and the premium spent on this trade was 5.38 sigmas above the mean, placing it in th... | Abbvie Declares $1.48 Dividend On February 16, 2023 the company declared a regular quarterly dividend of $1.48 per share ($5.92 annualized). On May 1, 2023 at 11:32:44 ET an unusually large $1,585.00K block of Put contracts in Abbvie (ABBV) was sold, with a strike price of $150.00 / share, expiring in 627 day(s) (on Ja... | On May 1, 2023 at 11:32:44 ET an unusually large $1,585.00K block of Put contracts in Abbvie (ABBV) was sold, with a strike price of $150.00 / share, expiring in 627 day(s) (on January 17, 2025). Fintel tracks all large options trades, and the premium spent on this trade was 5.38 sigmas above the mean, placing it in th... |
22,580 | 2023-05-01 00:00:00 UTC | Notable Monday Option Activity: ABBV, ORCL, MTCH | ABBV | https://www.nasdaq.com/articles/notable-monday-option-activity%3A-abbv-orcl-mtch | null | null | Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in AbbVie Inc (Symbol: ABBV), where a total of 27,571 contracts have traded so far, representing approximately 2.8 million underlying shares. That amounts to about 52.6% of ABBV's average daily trading volume over the p... | Especially high volume was seen for the $165 strike put option expiring May 19, 2023, with 3,505 contracts trading so far today, representing approximately 350,500 underlying shares of ABBV. Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in AbbVie Inc (Symbol: ABBV)... | Below is a chart showing ABBV's trailing twelve month trading history, with the $165 strike highlighted in orange: Oracle Corp (Symbol: ORCL) options are showing a volume of 36,899 contracts thus far today. Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in AbbVie In... | Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in AbbVie Inc (Symbol: ABBV), where a total of 27,571 contracts have traded so far, representing approximately 2.8 million underlying shares. Below is a chart showing MTCH's trailing twelve month trading history, with t... | Especially high volume was seen for the $165 strike put option expiring May 19, 2023, with 3,505 contracts trading so far today, representing approximately 350,500 underlying shares of ABBV. Below is a chart showing MTCH's trailing twelve month trading history, with the $42.50 strike highlighted in orange: For the vari... |
22,581 | 2023-05-01 00:00:00 UTC | Where Will AbbVie Be in 5 Years? | ABBV | https://www.nasdaq.com/articles/where-will-abbvie-be-in-5-years | null | null | On paper, drugmaker AbbVie (NYSE: ABBV) isn't having the best year. The company recently lost patent exclusivity in the U.S for its biggest cash cow, immunology medicine Humira. This product has been the key asset for AbbVie over the 10 years since it split from Abbott Laboratories, so this is a big deal.
But even if A... | Considering that Humira alone made up about 37% of AbbVie's total revenue in 2022, it's not surprising that management expects its top line to decline for the next couple of years. On paper, drugmaker AbbVie (NYSE: ABBV) isn't having the best year. This product has been the key asset for AbbVie over the 10 years since ... | On paper, drugmaker AbbVie (NYSE: ABBV) isn't having the best year. This product has been the key asset for AbbVie over the 10 years since it split from Abbott Laboratories, so this is a big deal. But even if AbbVie is nearly synonymous with Humira, can the company rise above this massive headwind and deliver solid ret... | Considering that Humira alone made up about 37% of AbbVie's total revenue in 2022, it's not surprising that management expects its top line to decline for the next couple of years. Expect brand-new products In addition to its current lineup, AbbVie expects to launch new products over the coming few years that will help... | So expect AbbVie to still be a Dividend King in five years. * They just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! On paper, drugmaker AbbVie (NYSE: ABBV) isn't having the best year. |
22,582 | 2023-05-01 00:00:00 UTC | Guru Fundamental Report for ABBV | ABBV | https://www.nasdaq.com/articles/guru-fundamental-report-for-abbv-21 | null | null | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanr... |
22,583 | 2023-05-01 00:00:00 UTC | AbbVie Stock Plunged: Should You Buy the Dip? | ABBV | https://www.nasdaq.com/articles/abbvie-stock-plunged%3A-should-you-buy-the-dip | null | null | AbbVie (NYSE: ABBV) spent 11 weeks building solid momentum. Its stock climbed more than 14% during the period. But it took only one day to wipe out most of the gain.
The drugmaker's shares plunged last Thursday after AbbVie announced its first-quarter results. Although the pharma stock rebounded slightly on Friday, it'... | Senior vice president Carrie Strom, who heads up AbbVie's aesthetics business, said in the quarterly update that the Chinese market reopened faster than anticipated and the U.S. economy was a little stronger than projected. AbbVie president Rob Michael stated in the Q1 call, "Growth rates in the first quarter for both ... | AbbVie president Rob Michael stated in the Q1 call, "Growth rates in the first quarter for both products are consistent with our full-year expectations." AbbVie (NYSE: ABBV) spent 11 weeks building solid momentum. The drugmaker's shares plunged last Thursday after AbbVie announced its first-quarter results. | Why AbbVie stock was hit so hard There were several factors behind why AbbVie stock crashed last week. 10 stocks we like better than AbbVie When our analyst team has a stock tip, it can pay to listen. See the 10 stocks *Stock Advisor returns as of April 24, 2023 Keith Speights has positions in AbbVie. | Why AbbVie stock was hit so hard There were several factors behind why AbbVie stock crashed last week. AbbVie appears to be a solid stock to buy on the dip, in my view. AbbVie (NYSE: ABBV) spent 11 weeks building solid momentum. |
22,584 | 2023-04-30 00:00:00 UTC | AbbVie's Blockbuster Is Falling Fast. Time to Sell? | ABBV | https://www.nasdaq.com/articles/abbvies-blockbuster-is-falling-fast.-time-to-sell | null | null | Last week wasn't a great one for a lot of pharmaceutical stock investors. Shares of AbbVie (NYSE: ABBV) dropped by about 8% on Thursday, April 27. The market was responding to an earnings report that was the company's first since its lead product, Humira, lost patent-protected exclusivity in the U.S. market.
Humira los... | Humira losing market share to Amgen's Amjevita and other biosimilars isn't the only reason AbbVie's stock tanked. Wall Street analysts who follow AbbVie were quick to point out decelerating sales growth for two recently launched drugs that are expected to offset Humira's losses. Shares of AbbVie (NYSE: ABBV) dropped by... | Humira losing market share to Amgen's Amjevita and other biosimilars isn't the only reason AbbVie's stock tanked. Wall Street analysts who follow AbbVie were quick to point out decelerating sales growth for two recently launched drugs that are expected to offset Humira's losses. Skyrizi $1.40 billion 75% $1.58 billion ... | Humira losing market share to Amgen's Amjevita and other biosimilars isn't the only reason AbbVie's stock tanked. Wall Street analysts who follow AbbVie were quick to point out decelerating sales growth for two recently launched drugs that are expected to offset Humira's losses. Shares of AbbVie (NYSE: ABBV) dropped by... | Humira losing market share to Amgen's Amjevita and other biosimilars isn't the only reason AbbVie's stock tanked. * They just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! Shares of AbbVie (NYSE: ABBV) dropped by about 8% on Thursday, April 27. |
22,585 | 2023-04-29 00:00:00 UTC | 3 Unstoppable Stocks to Buy Right Now | ABBV | https://www.nasdaq.com/articles/3-unstoppable-stocks-to-buy-right-now | null | null | The laws of physics apply in some ways to investing. For example, some stocks have inertia -- they just can't break out of their rut. Others, though, either have momentum or the likelihood of gaining it in the future. Those are the kinds of stocks that are hard to keep down.
Three Motley Fool contributors have thoughts... | Here's why they chose AbbVie (NYSE: ABBV), Pfizer (NYSE: PFE), and Vertex Pharmaceuticals (NASDAQ: VRTX). Multiple blockbusters to build its business around David Jagielski (AbbVie): This year will undoubtedly be a tough one for AbbVie. But the business's long-term trajectory remains solid because AbbVie has a plan. | Here's why they chose AbbVie (NYSE: ABBV), Pfizer (NYSE: PFE), and Vertex Pharmaceuticals (NASDAQ: VRTX). Multiple blockbusters to build its business around David Jagielski (AbbVie): This year will undoubtedly be a tough one for AbbVie. But the business's long-term trajectory remains solid because AbbVie has a plan. | Here's why they chose AbbVie (NYSE: ABBV), Pfizer (NYSE: PFE), and Vertex Pharmaceuticals (NASDAQ: VRTX). Multiple blockbusters to build its business around David Jagielski (AbbVie): This year will undoubtedly be a tough one for AbbVie. But the business's long-term trajectory remains solid because AbbVie has a plan. | Keith Speights has positions in AbbVie, Pfizer, and Vertex Pharmaceuticals. Here's why they chose AbbVie (NYSE: ABBV), Pfizer (NYSE: PFE), and Vertex Pharmaceuticals (NASDAQ: VRTX). Multiple blockbusters to build its business around David Jagielski (AbbVie): This year will undoubtedly be a tough one for AbbVie. |
22,586 | 2023-04-28 00:00:00 UTC | AbbVie (ABBV) Q1 2023 Earnings Call Transcript | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-q1-2023-earnings-call-transcript | null | null | Image source: The Motley Fool.
AbbVie (NYSE: ABBV)
Q1 2023 Earnings Call
Apr 27, 2023, 9:00 a.m. ET
Contents:
Prepared Remarks
Questions and Answers
Call Participants
Prepared Remarks:
Operator
Good morning, and thank you for standing by. Welcome to the AbbVie first quarter 2023earnings conference call All participant... | AbbVie (NYSE: ABBV) Q1 2023 Earnings Call Apr 27, 2023, 9:00 a.m. Welcome to the AbbVie first quarter 2023earnings conference call All participants will be able to listen-only until the question-and-answer portion of this call. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties... | Operator [Operator signoff] Duration: 0 minutes Call participants: Liz Shea -- Vice President, Investor Relations Rick Gonzalez -- Chairman and Chief Executive Officer Rob Michael -- Vice Chairman and President Jeff Stewart -- Executive Vice President, Chief Commercial Officer Carrie Strom -- Senior Vice President, Abb... | Operator [Operator signoff] Duration: 0 minutes Call participants: Liz Shea -- Vice President, Investor Relations Rick Gonzalez -- Chairman and Chief Executive Officer Rob Michael -- Vice Chairman and President Jeff Stewart -- Executive Vice President, Chief Commercial Officer Carrie Strom -- Senior Vice President, Abb... | Operator [Operator signoff] Duration: 0 minutes Call participants: Liz Shea -- Vice President, Investor Relations Rick Gonzalez -- Chairman and Chief Executive Officer Rob Michael -- Vice Chairman and President Jeff Stewart -- Executive Vice President, Chief Commercial Officer Carrie Strom -- Senior Vice President, Abb... |
22,587 | 2023-04-28 00:00:00 UTC | Wells Fargo Maintains Abbvie (ABBV) Overweight Recommendation | ABBV | https://www.nasdaq.com/articles/wells-fargo-maintains-abbvie-abbv-overweight-recommendation | null | null | Fintel reports that on April 28, 2023, Wells Fargo maintained coverage of Abbvie (NYSE:ABBV) with a Overweight recommendation.
Analyst Price Forecast Suggests 13.11% Upside
As of April 24, 2023, the average one-year price target for Abbvie is 168.39. The forecasts range from a low of 136.35 to a high of $210.00. The av... | Fintel reports that on April 28, 2023, Wells Fargo maintained coverage of Abbvie (NYSE:ABBV) with a Overweight recommendation. AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. Analyst Price Forecast Suggests 13.11% Up... | Fintel reports that on April 28, 2023, Wells Fargo maintained coverage of Abbvie (NYSE:ABBV) with a Overweight recommendation. Analyst Price Forecast Suggests 13.11% Upside As of April 24, 2023, the average one-year price target for Abbvie is 168.39. The projected annual revenue for Abbvie is 55,229MM, a decrease of 2.... | Abbvie Declares $1.48 Dividend On February 16, 2023 the company declared a regular quarterly dividend of $1.48 per share ($5.92 annualized). Fintel reports that on April 28, 2023, Wells Fargo maintained coverage of Abbvie (NYSE:ABBV) with a Overweight recommendation. Analyst Price Forecast Suggests 13.11% Upside As of ... | Analyst Price Forecast Suggests 13.11% Upside As of April 24, 2023, the average one-year price target for Abbvie is 168.39. Fintel reports that on April 28, 2023, Wells Fargo maintained coverage of Abbvie (NYSE:ABBV) with a Overweight recommendation. The projected annual revenue for Abbvie is 55,229MM, a decrease of 2.... |
22,588 | 2023-04-28 00:00:00 UTC | Morgan Stanley Maintains Abbvie (ABBV) Overweight Recommendation | ABBV | https://www.nasdaq.com/articles/morgan-stanley-maintains-abbvie-abbv-overweight-recommendation-0 | null | null | Fintel reports that on April 28, 2023, Morgan Stanley maintained coverage of Abbvie (NYSE:ABBV) with a Overweight recommendation.
Analyst Price Forecast Suggests 13.11% Upside
As of April 24, 2023, the average one-year price target for Abbvie is 168.39. The forecasts range from a low of 136.35 to a high of $210.00. The... | Fintel reports that on April 28, 2023, Morgan Stanley maintained coverage of Abbvie (NYSE:ABBV) with a Overweight recommendation. AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. Analyst Price Forecast Suggests 13.11%... | Fintel reports that on April 28, 2023, Morgan Stanley maintained coverage of Abbvie (NYSE:ABBV) with a Overweight recommendation. Analyst Price Forecast Suggests 13.11% Upside As of April 24, 2023, the average one-year price target for Abbvie is 168.39. The projected annual revenue for Abbvie is 55,229MM, a decrease of... | Abbvie Declares $1.48 Dividend On February 16, 2023 the company declared a regular quarterly dividend of $1.48 per share ($5.92 annualized). Fintel reports that on April 28, 2023, Morgan Stanley maintained coverage of Abbvie (NYSE:ABBV) with a Overweight recommendation. Analyst Price Forecast Suggests 13.11% Upside As ... | Analyst Price Forecast Suggests 13.11% Upside As of April 24, 2023, the average one-year price target for Abbvie is 168.39. Fintel reports that on April 28, 2023, Morgan Stanley maintained coverage of Abbvie (NYSE:ABBV) with a Overweight recommendation. The projected annual revenue for Abbvie is 55,229MM, a decrease of... |
22,589 | 2023-04-28 00:00:00 UTC | Guru Fundamental Report for ABBV | ABBV | https://www.nasdaq.com/articles/guru-fundamental-report-for-abbv-20 | null | null | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanr... |
22,590 | 2023-04-28 00:00:00 UTC | Guggenheim Maintains Abbvie (ABBV) Buy Recommendation | ABBV | https://www.nasdaq.com/articles/guggenheim-maintains-abbvie-abbv-buy-recommendation | null | null | Fintel reports that on April 28, 2023, Guggenheim maintained coverage of Abbvie (NYSE:ABBV) with a Buy recommendation.
Analyst Price Forecast Suggests 13.11% Upside
As of April 24, 2023, the average one-year price target for Abbvie is 168.39. The forecasts range from a low of 136.35 to a high of $210.00. The average pr... | AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. Fintel reports that on April 28, 2023, Guggenheim maintained coverage of Abbvie (NYSE:ABBV) with a Buy recommendation. Analyst Price Forecast Suggests 13.11% Upside As ... | Fintel reports that on April 28, 2023, Guggenheim maintained coverage of Abbvie (NYSE:ABBV) with a Buy recommendation. Analyst Price Forecast Suggests 13.11% Upside As of April 24, 2023, the average one-year price target for Abbvie is 168.39. The projected annual revenue for Abbvie is 55,229MM, a decrease of 2.66%. | Abbvie Declares $1.48 Dividend On February 16, 2023 the company declared a regular quarterly dividend of $1.48 per share ($5.92 annualized). Fintel reports that on April 28, 2023, Guggenheim maintained coverage of Abbvie (NYSE:ABBV) with a Buy recommendation. Analyst Price Forecast Suggests 13.11% Upside As of April 24... | Fintel reports that on April 28, 2023, Guggenheim maintained coverage of Abbvie (NYSE:ABBV) with a Buy recommendation. Analyst Price Forecast Suggests 13.11% Upside As of April 24, 2023, the average one-year price target for Abbvie is 168.39. The projected annual revenue for Abbvie is 55,229MM, a decrease of 2.66%. |
22,591 | 2023-04-28 00:00:00 UTC | 5 Dividend Aristocrats Where Analysts See Capital Gains | ABBV | https://www.nasdaq.com/articles/5-dividend-aristocrats-where-analysts-see-capital-gains-81 | null | null | To become a "Dividend Aristocrat," a dividend paying company must accomplish an incredible feat: consistently increase shareholder dividends every year for at least 20 consecutive years. Companies with this kind of track record tend to attract a lot of investor attention — and furthermore, "tracking" funds that follow ... | AbbVie Inc (Symbol: ABBV) $148.87 $168.14 12.95% Brady Corp (Symbol: BRC) $50.69 $56.50 11.46% Lowe's Companies Inc (Symbol: LOW) $204.53 $227.69 11.33% RLI Corp (Symbol: RLI) $141.15 $156.50 10.87% NIKE Inc (Symbol: NKE) $125.70 $138.17 9.92% The average 12-month analyst targets are only targets for the share price ho... | AbbVie Inc (Symbol: ABBV) $148.87 $168.14 12.95% Brady Corp (Symbol: BRC) $50.69 $56.50 11.46% Lowe's Companies Inc (Symbol: LOW) $204.53 $227.69 11.33% RLI Corp (Symbol: RLI) $141.15 $156.50 10.87% NIKE Inc (Symbol: NKE) $125.70 $138.17 9.92% The average 12-month analyst targets are only targets for the share price ho... | AbbVie Inc (Symbol: ABBV) $148.87 $168.14 12.95% Brady Corp (Symbol: BRC) $50.69 $56.50 11.46% Lowe's Companies Inc (Symbol: LOW) $204.53 $227.69 11.33% RLI Corp (Symbol: RLI) $141.15 $156.50 10.87% NIKE Inc (Symbol: NKE) $125.70 $138.17 9.92% The average 12-month analyst targets are only targets for the share price ho... | AbbVie Inc (Symbol: ABBV) $148.87 $168.14 12.95% Brady Corp (Symbol: BRC) $50.69 $56.50 11.46% Lowe's Companies Inc (Symbol: LOW) $204.53 $227.69 11.33% RLI Corp (Symbol: RLI) $141.15 $156.50 10.87% NIKE Inc (Symbol: NKE) $125.70 $138.17 9.92% The average 12-month analyst targets are only targets for the share price ho... |
22,592 | 2023-04-28 00:00:00 UTC | How AI Is Revolutionizing Tech, and Why You Should Invest in These Leading Companies | ABBV | https://www.nasdaq.com/articles/how-ai-is-revolutionizing-tech-and-why-you-should-invest-in-these-leading-companies | null | null | Artificial intelligence (AI) permeated industries for years, but the release of ChatGPT thrust it into the limelight. It's the talk of the investment community and around the water coolers across the country. But what exactly is it?
AI extends far beyond "intelligent" (and sometimes sinister) robots in the movies or Ch... | Companies like AbbVie (NYSE: ABBV) are harnessing AI's ability to spot patterns and sift through massive amounts of data for drug discovery. There are several reasons to love AbbVie, like its $58 billion in 2022 revenue and $25 billion operating cash flow, its impressive portfolio of drugs in development, and 4% divide... | Companies like AbbVie (NYSE: ABBV) are harnessing AI's ability to spot patterns and sift through massive amounts of data for drug discovery. There are several reasons to love AbbVie, like its $58 billion in 2022 revenue and $25 billion operating cash flow, its impressive portfolio of drugs in development, and 4% divide... | There are several reasons to love AbbVie, like its $58 billion in 2022 revenue and $25 billion operating cash flow, its impressive portfolio of drugs in development, and 4% dividend, which has risen every year since the company was formed in 2013. Biosimilars for the company's drug Humira were released in the U.S. this... | Companies like AbbVie (NYSE: ABBV) are harnessing AI's ability to spot patterns and sift through massive amounts of data for drug discovery. There are several reasons to love AbbVie, like its $58 billion in 2022 revenue and $25 billion operating cash flow, its impressive portfolio of drugs in development, and 4% divide... |
22,593 | 2023-04-27 00:00:00 UTC | US STOCKS-Wall St rallies as earnings season boost offsets economy worries | ABBV | https://www.nasdaq.com/articles/us-stocks-wall-st-rallies-as-earnings-season-boost-offsets-economy-worries | null | null | By Sinéad Carew, Sruthi Shankar and Ankika Biswas
April 27 (Reuters) - The tech-heavy Nasdaq led a Wall Street rally on Thursday as a strong quarterly report from Facebook parent Meta Platforms Inc overshadowed concerns over slowing U.S. economic growth.
Shares in Meta META.Osoared to touch the highest in more than a y... | AbbVie Inc ABBV.N fell sharply after the drugmaker missed quarterly revenue estimates for its newer treatments, while heavy machinery maker Caterpillar Inc CAT.N dipped as a flat order backlog signaled demand may have peaked. By Sinéad Carew, Sruthi Shankar and Ankika Biswas April 27 (Reuters) - The tech-heavy Nasdaq l... | AbbVie Inc ABBV.N fell sharply after the drugmaker missed quarterly revenue estimates for its newer treatments, while heavy machinery maker Caterpillar Inc CAT.N dipped as a flat order backlog signaled demand may have peaked. By Sinéad Carew, Sruthi Shankar and Ankika Biswas April 27 (Reuters) - The tech-heavy Nasdaq l... | AbbVie Inc ABBV.N fell sharply after the drugmaker missed quarterly revenue estimates for its newer treatments, while heavy machinery maker Caterpillar Inc CAT.N dipped as a flat order backlog signaled demand may have peaked. By Sinéad Carew, Sruthi Shankar and Ankika Biswas April 27 (Reuters) - The tech-heavy Nasdaq l... | AbbVie Inc ABBV.N fell sharply after the drugmaker missed quarterly revenue estimates for its newer treatments, while heavy machinery maker Caterpillar Inc CAT.N dipped as a flat order backlog signaled demand may have peaked. By Sinéad Carew, Sruthi Shankar and Ankika Biswas April 27 (Reuters) - The tech-heavy Nasdaq l... |
22,594 | 2023-04-27 00:00:00 UTC | Drugmakers scout for deals, ramp up research spending | ABBV | https://www.nasdaq.com/articles/drugmakers-scout-for-deals-ramp-up-research-spending | null | null | By Manas Mishra and Patrick Wingrove
April 27 (Reuters) - Drugmakers including Merck & Co MRK.N, AstraZeneca Plc AZN.L and AbbVie Inc ABBV.N said on Thursday they are open to acquisitions and reported a ramp up in research and development spending as the industry's larger players look for new sources of future revenue.... | By Manas Mishra and Patrick Wingrove April 27 (Reuters) - Drugmakers including Merck & Co MRK.N, AstraZeneca Plc AZN.L and AbbVie Inc ABBV.N said on Thursday they are open to acquisitions and reported a ramp up in research and development spending as the industry's larger players look for new sources of future revenue.... | By Manas Mishra and Patrick Wingrove April 27 (Reuters) - Drugmakers including Merck & Co MRK.N, AstraZeneca Plc AZN.L and AbbVie Inc ABBV.N said on Thursday they are open to acquisitions and reported a ramp up in research and development spending as the industry's larger players look for new sources of future revenue.... | By Manas Mishra and Patrick Wingrove April 27 (Reuters) - Drugmakers including Merck & Co MRK.N, AstraZeneca Plc AZN.L and AbbVie Inc ABBV.N said on Thursday they are open to acquisitions and reported a ramp up in research and development spending as the industry's larger players look for new sources of future revenue.... | AbbVie on Thursday reported sales that missed estimates for most treatments, including its blockbuster arthritis drug Humira, and its shares closed down 8%. Humira's U.S. sales fell 26.1% in the quarter to $2.95 billion as it faced its first biosimilar competition from Amgen's AMGN.O Amjevita, and AbbVie forecast a ste... |
22,595 | 2023-04-27 00:00:00 UTC | US STOCKS-Wall St rallies as earnings season boost offsets economy worries | ABBV | https://www.nasdaq.com/articles/us-stocks-wall-st-rallies-as-earnings-season-boost-offsets-economy-worries-0 | null | null | By Sinéad Carew, Sruthi Shankar and Ankika Biswas
April 27 (Reuters) - The tech-heavy Nasdaq led a Wall Street rally on Thursday as a strong quarterly report from Facebook parent Meta Platforms Inc overshadowed concerns over slowing U.S. economic growth.
Shares in Meta META.O closed up 13.9% after touching their highes... | AbbVie Inc ABBV.N fell about 8% after the drugmaker missed quarterly revenue estimates for its newer treatments, while heavy machinery maker Caterpillar Inc CAT.N dipped as a flat order backlog signaled demand may have peaked. By Sinéad Carew, Sruthi Shankar and Ankika Biswas April 27 (Reuters) - The tech-heavy Nasdaq ... | AbbVie Inc ABBV.N fell about 8% after the drugmaker missed quarterly revenue estimates for its newer treatments, while heavy machinery maker Caterpillar Inc CAT.N dipped as a flat order backlog signaled demand may have peaked. By Sinéad Carew, Sruthi Shankar and Ankika Biswas April 27 (Reuters) - The tech-heavy Nasdaq ... | AbbVie Inc ABBV.N fell about 8% after the drugmaker missed quarterly revenue estimates for its newer treatments, while heavy machinery maker Caterpillar Inc CAT.N dipped as a flat order backlog signaled demand may have peaked. By Sinéad Carew, Sruthi Shankar and Ankika Biswas April 27 (Reuters) - The tech-heavy Nasdaq ... | AbbVie Inc ABBV.N fell about 8% after the drugmaker missed quarterly revenue estimates for its newer treatments, while heavy machinery maker Caterpillar Inc CAT.N dipped as a flat order backlog signaled demand may have peaked. By Sinéad Carew, Sruthi Shankar and Ankika Biswas April 27 (Reuters) - The tech-heavy Nasdaq ... |
22,596 | 2023-04-27 00:00:00 UTC | AbbVie (ABBV) Shares Cross 4% Yield Mark | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-shares-cross-4-yield-mark-0 | null | null | Looking at the universe of stocks we cover at Dividend Channel, in trading on Thursday, shares of AbbVie Inc (Symbol: ABBV) were yielding above the 4% mark based on its quarterly dividend (annualized to $5.92), with the stock changing hands as low as $147.16 on the day. Dividends are particularly important for investor... | Looking at the universe of stocks we cover at Dividend Channel, in trading on Thursday, shares of AbbVie Inc (Symbol: ABBV) were yielding above the 4% mark based on its quarterly dividend (annualized to $5.92), with the stock changing hands as low as $147.16 on the day. AbbVie Inc (Symbol: ABBV) is an S&P 500 company, ... | Looking at the universe of stocks we cover at Dividend Channel, in trading on Thursday, shares of AbbVie Inc (Symbol: ABBV) were yielding above the 4% mark based on its quarterly dividend (annualized to $5.92), with the stock changing hands as low as $147.16 on the day. AbbVie Inc (Symbol: ABBV) is an S&P 500 company, ... | Looking at the universe of stocks we cover at Dividend Channel, in trading on Thursday, shares of AbbVie Inc (Symbol: ABBV) were yielding above the 4% mark based on its quarterly dividend (annualized to $5.92), with the stock changing hands as low as $147.16 on the day. AbbVie Inc (Symbol: ABBV) is an S&P 500 company, ... | Looking at the universe of stocks we cover at Dividend Channel, in trading on Thursday, shares of AbbVie Inc (Symbol: ABBV) were yielding above the 4% mark based on its quarterly dividend (annualized to $5.92), with the stock changing hands as low as $147.16 on the day. AbbVie Inc (Symbol: ABBV) is an S&P 500 company, ... |
22,597 | 2023-04-27 00:00:00 UTC | US STOCKS-Wall St rallies as Meta earnings offset economy worries | ABBV | https://www.nasdaq.com/articles/us-stocks-wall-st-rallies-as-meta-earnings-offset-economy-worries-0 | null | null | For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window.
Lower inventories restrains Q1 US economic growth
Meta up, touts AI might as digital ads boost outlook
Eli Lilly up on annual profit forecast raise
Amazon.com soars, earnings due after market close
Indexes up: Do... | AbbVie Inc ABBV.N fell 87.4% after the drugmaker missed quarterly revenue estimates for its newer treatments, while heavy machinery maker Caterpillar Inc CAT.N dipped 1.8% as a flat order backlog signaled demand may have peaked. Lower inventories restrains Q1 US economic growth Meta up, touts AI might as digital ads bo... | AbbVie Inc ABBV.N fell 87.4% after the drugmaker missed quarterly revenue estimates for its newer treatments, while heavy machinery maker Caterpillar Inc CAT.N dipped 1.8% as a flat order backlog signaled demand may have peaked. Lower inventories restrains Q1 US economic growth Meta up, touts AI might as digital ads bo... | AbbVie Inc ABBV.N fell 87.4% after the drugmaker missed quarterly revenue estimates for its newer treatments, while heavy machinery maker Caterpillar Inc CAT.N dipped 1.8% as a flat order backlog signaled demand may have peaked. Lower inventories restrains Q1 US economic growth Meta up, touts AI might as digital ads bo... | AbbVie Inc ABBV.N fell 87.4% after the drugmaker missed quarterly revenue estimates for its newer treatments, while heavy machinery maker Caterpillar Inc CAT.N dipped 1.8% as a flat order backlog signaled demand may have peaked. Lower inventories restrains Q1 US economic growth Meta up, touts AI might as digital ads bo... |
22,598 | 2023-04-27 00:00:00 UTC | Why AbbVie Stock Is Crashing Today | ABBV | https://www.nasdaq.com/articles/why-abbvie-stock-is-crashing-today | null | null | What happened
Shares of the pharmaceutical giant AbbVie (NYSE: ABBV) fell by as much as 9% in early morning trading Thursday. The drugmaker's shares have recovered since hitting this intra-day low, but they were still down by a hefty 7.8% as of 1:14 p.m. ET Thursday afternoon.
What sparked this sell-off? Ahead of the o... | Specifically, AbbVie's portion of sales from the blood cancer drug Imbruvica dropped by 27% in the U.S. and 19.7% internationally, reflecting increased competition in the hotly contested BTK inhibitor space. AbbVie also reported a 5.4% dip in global medical aesthetics sales in the first quarter of the year, thanks in l... | So what The headline from AbbVie's latest financial report is that its flagship immunology medicine, Humira, saw a 26.1% dip in U.S. sales and a 20% drop in international sales during the three-month period, relative to the same period a year ago. AbbVie also reported a 5.4% dip in global medical aesthetics sales in th... | So what The headline from AbbVie's latest financial report is that its flagship immunology medicine, Humira, saw a 26.1% dip in U.S. sales and a 20% drop in international sales during the three-month period, relative to the same period a year ago. 10 stocks we like better than AbbVie When our analyst team has a stock t... | * They just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! What happened Shares of the pharmaceutical giant AbbVie (NYSE: ABBV) fell by as much as 9% in early morning trading Thursday. Ahead of the opening bell, AbbVie reported 2023 first-quater earni... |
22,599 | 2023-04-27 00:00:00 UTC | AbbVie (ABBV) Q1 Earnings Beat, Skyrizi Sales Underperform | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-q1-earnings-beat-skyrizi-sales-underperform | null | null | AbbVie Inc. ABBV reported adjusted earnings of $2.46 per share for the first quarter of 2023, beating the Zacks Consensus Estimate and our estimate, which stood at $2.44 and $2.40, respectively. The reported earnings also exceeded the guidance of $2.31-$2.41. Earnings declined 22.2% year over year.
ABBV’s revenues of $... | Quarter in Detail In immunology, AbbVie’s flagship drug Humira recorded a year-over-year sales decline of 24.3% to $3.54 billion on an operational basis. Like Amgen, several other companies like Biogen, Boehringer Ingelheim, Novartis NVS and Pfizer have received FDA approvals for their own Humira biosimilars, many of w... | AbbVie’s oncology/hematology (including Imbruvica and Venclexta) sales declined 12.9% on an operational basis to $1.42 billion in the quarter, as growth of Venclexta sales, was more than offset by lower U.S. sales of Imbruvica. Click to get this free report Novartis AG (NVS) : Free Stock Analysis Report Johnson & Johns... | AbbVie’s oncology/hematology (including Imbruvica and Venclexta) sales declined 12.9% on an operational basis to $1.42 billion in the quarter, as growth of Venclexta sales, was more than offset by lower U.S. sales of Imbruvica. Click to get this free report Novartis AG (NVS) : Free Stock Analysis Report Johnson & Johns... | AbbVie Inc. ABBV reported adjusted earnings of $2.46 per share for the first quarter of 2023, beating the Zacks Consensus Estimate and our estimate, which stood at $2.44 and $2.40, respectively. AbbVie’s aesthetics portfolio sales were down 2.0% on an operational basis to $1.30 billion. ABBV’s revenues of $12.23 billio... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.